32720531		Gene therapy and immunotherapy as promising strategies to combat diseaseD006816-associated diseaseD019636: emphasis on recent updates and future perspectives.INTRODUCTION: Modulation of gene expression using gene therapy as well as modulation of immune activation using immunotherapy has attracted considerable attention as rapidly emerging potential therapeutic intervention for the treatment of diseaseD006816. Several preclinical and clinical trials for gene-based therapy and immunotherapy/antibody-based have been conducted. AREAS COVERED: This review focused on the potential use of gene therapy and immuno-based therapies to treat diseaseD006816, including the current status, the rationale for these approaches as well as preclinical and clinical data supporting it. Growing knowledge of diseaseD006816 pathogenesis has resulted in the discovery of new therapeutic targets, some of which are now in clinical trials. Focus has been allocated to RNA and DNA-based gene therapies for the reduction of mutant ncbi3064 (mHTT), using Immuno/antibody-based therapies. EXPERT OPINION: While safety and efficacy of gene therapy and immunotherapy has been well demonstrated for diseaseD006816, therefore much focus has now been shifted to disease-modifying therapies. This review defines the current status and future directions of gene therapy and immunotherapies. The review summarizes by what means diseaseD006816 genetic root cause modification and functional restoration of mHtt protein could be achieved by using targeted multimodality gene therapy and immunotherapy to target intracellular and extracellular mHtt.
37306313	Association|diseaseD006816|ncbi3064	Selective perforant-pathway diseaseD001284 in diseaseD006816: MRI analysis of hippocampal subfields.INTRODUCTION: While individuals with diseaseD006816 (diseaseD006816) show diseaseD008569 that indicates diseaseD001927, the available literature does not consistently identify structural evidence for involvement of the whole hippocampus but rather suggests that diseaseD001284 may be confined to certain hippocampal subregions. METHODS: We processed T1-weighted MRI from IMAGE-diseaseD006816 study using FreeSurfer 7.0 and compared the volumes of the hippocampal subfields among 36 early motor symptomatic (symp-diseaseD006816), 40 pre-symptomatic (pre-diseaseD006816), and 36 healthy control individuals across three timepoints over 36 months. RESULTS: Mixed-model analyses revealed significantly lower subfield volumes in symp-diseaseD006816, compared with pre-diseaseD006816 and control groups, in the subicular regions of the perforant-pathway: presubiculum, subiculum, dentate gyrus, tail, and right molecular layer. These adjoining subfields aggregated into a single principal component, which demonstrated an accelerated rate of diseaseD001284 in the symp-diseaseD006816. Volumes between pre-diseaseD006816 and controls did not show any significant difference. In the combined diseaseD006816 groups, CAG repeat length and disease burden score were associated with presubiculum, molecular layer, tail, and perforant-pathway subfield volumes. Hippocampal left tail and perforant-pathway subfields were associated with motor onset in the pre-diseaseD006816 group. CONCLUSIONS: Hippocampal subfields diseaseD001284 in early symptomatic diseaseD006816 affects key regions of the perforant-pathway, which may implicate the distinctive diseaseD008569 at this stage of illness. Their volumetric associations with genetic and clinical markers suggest the selective susceptibility of these subfields to mutant ncbi3064 and disease progression.
33567536		A Novel Triplet-Primed PCR Assay to Detect the Full Range of Trinucleotide CAG Repeats in the ncbi3064 Gene (HTT).The expanded CAG repeat number in HTT gene causes diseaseD006816 (diseaseD006816), which is a severe, dominant diseaseD019636. The accurate determination of the expanded allele size is crucial to confirm the genetic status in symptomatic and presymptomatic at-risk subjects and avoid genetic polymorphism-related false-negative diagnoses. Precise CAG repeat number determination is critical to discriminate the cutoff between unexpanded and intermediate mutable alleles (IAs, 27-35 CAG) as well as between IAs and pathological, low-penetrance alleles (i.e., 36-39 CAG repeats), and it is also critical to detect large repeat expansions causing pediatric diseaseD006816 variants. We analyzed the HTT-CAG repeat number of 14 DNA reference materials and of a DNA collection of 43 additional samples carrying unexpanded, IAs, low and complete penetrance alleles, including large (>60 repeats) and very large (>100 repeats) expansions using a novel triplet-primed PCR-based assay, the AmplideX PCR/CE HTT Kit. The results demonstrate that the method accurately genotypes both normal and expanded HTT-CAG repeat numbers and reveals previously undisclosed and very large CAG expansions >200 repeats. We also show that this technique can improve genetic test reliability and accuracy by detecting CAG expansions in samples with sequence variations within or adjacent to the repeat tract that cause allele drop-outs or inaccuracies using other PCR methods.
33871905		svReg: Structural varying-coefficient regression to differentiate how regional diseaseC566985 affects diseaseD000068079 for diseaseD006816 severity groups.For diseaseD006816, identification of brain regions related to diseaseD000068079 can be useful for developing interventions to alleviate the motor symptom, the major symptom of the disease. However, the effects from the brain regions to diseaseD000068079 may vary for different groups of 9606. Hence, our interest is not only to identify the brain regions but also to understand how their effects on diseaseD000068079 differ by 9606 groups. This can be cast as a model selection problem for a varying-coefficient regression. However, this is challenging when there is a pre-specified group structure among variables. We propose a novel variable selection method for a varying-coefficient regression with such structured variables and provide a publicly available R package svreg for implementation of our method. Our method is empirically shown to select relevant variables consistently. Also, our method screens irrelevant variables better than existing methods. Hence, our method leads to a model with higher sensitivity, lower false discovery rate and higher prediction accuracy than the existing methods. Finally, we found that the effects from the brain regions to diseaseD000068079 differ by disease severity of the 9606. To the best of our knowledge, our study is the first to identify such interaction effects between the disease severity and brain regions, which indicates the need for customized intervention by disease severity.
35695745	Negative_Correlation|chemicalD014805|diseaseD020146; Negative_Correlation|chemicalD014805|diseaseD014806; Negative_Correlation|chemicalD014805|diseaseD009069	Differentiation of Reversible Hemichorea Due to diseaseD014806 From diseaseD006816 Via chemicalD019788 PET.ABSTRACT: diseaseD014806 may present with diverse symptoms, complicating the differential diagnosis. diseaseD001480, for instance, are a rare manifestation of diseaseD014806. MRI of the brain frequently remains without conclusive findings. However, chemicalD019788 PET/CT may reveal characteristic changes in the metabolism of the basal ganglia and thus contribute to an accurate diagnosis. We demonstrate the case of a 9606 with left-sided diseaseD009069 due to diseaseD014806 showing a contralateral diseaseD020146, which normalized after chemicalD014805 supplementation, ruling out other deviating causes, particularly diseaseD006816.
33636389	Association|diseaseD006816|ncbi4747; Association|diseaseC566985|ncbi4747; Association|ncbi4747|ncbi6314; Positive_Correlation|diseaseD020754|ncbi4747; Association|ncbi4287|ncbi4747; Association|ncbi4747|ncbi836; Association|ncbi4747|ncbi6311	Plasma neurofilament light chain predicts diseaseD002526 and clinical progression in diseaseD020754.Neurofilament light chain (ncbi4747) is a marker of diseaseC566985 and predictor of disease progression in rare diseases such as diseaseD006816, but also in more common diseaseD009461 such as diseaseD000544. The aim of this study was to measure ncbi4747 longitudinally in autosomal dominant diseaseD020754 (diseaseD020754) and establish correlation with clinical and imaging parameters. We enrolled 62 pathological expansions carriers (17 ncbi836, 13 ncbi6311, 19 ncbi4287, and 13 ncbi6314) and 19 age-matched controls in a prospective biomarker study between 2011 and 2015 and followed for 24 months at the Paris Brain Institute. We performed neurological examination, brain 3 T MRI and plasma ncbi4747 measurements using an ultrasensitive single-molecule array at baseline and at the two-year follow-up visit. We evaluated ncbi4747 correlations with ages, CAG repeat sizes, clinical scores and volumetric brain MRIs. ncbi4747 levels were significantly higher in diseaseD020754 than controls at both time points (p < 0.001). Age-adjusted ncbi4747 levels were significantly correlated at baseline with clinical scores (p < 0.01). We identified optimal ncbi4747 cut-off concentrations to differentiate controls from carriers for each genotype (ncbi836 16.87 pg/mL, ncbi6311, 19.1 pg/mL, ncbi4287 16.04 pg/mL, ncbi6314 16.67 pg/mL). For all diseaseD020754, ncbi4747 concentration was stable over two years (p = 0.95) despite a clinical progression (p < 0.0001). Clinical progression between baseline and follow-up was associated with higher ncbi4747 concentrations at baseline (p = 0.04). Of note, all premanifest carriers with ncbi4747 levels close to cut off concentrations had signs of the disease at follow-up. For all diseaseD020754, the higher the observed ncbi4747, the lower the pons volume at baseline (p < 0.01) and follow-up (p = 0.02). Higher ncbi4747 levels at baseline in all diseaseD020754 predicted a decrease in cerebellar volume (p = 0.03). This result remained significant for ncbi6311 only among all genotypes (p = 0.02). Overall, plasma ncbi4747 levels at baseline in diseaseC565772 expansion carriers predict cerebellar volume change and clinical score progression. ncbi4747 levels might help refine inclusion criteria for clinical trials in carriers with very subtle signs.
32627533		Strategies for the Molecular Imaging of diseaseC000718787 and the Value of a Multimodal Approach.Protein aggregation has been widely implicated in diseaseD019636 such as diseaseD000544, diseaseD057180, diseaseD010300, and diseaseD006816, as well as in systemic diseaseD000686 and conditions associated with localized diseaseC000718787 deposits, such as diseaseD003924. The pressing need for a better understanding of the factors governing protein assembly has driven research for the development of molecular sensors for amyloidogenic proteins. To date, a number of sensors have been developed that report on the presence of protein aggregates utilizing various modalities, and their utility demonstrated for imaging protein aggregation in vitro and in vivo. Analysis of these sensors highlights the various advantages and disadvantages of the different imaging modalities and makes clear that multimodal sensors with properties amenable to more than one imaging technique need to be developed. This critical review highlights the key molecular scaffolds reported for molecular imaging modalities such as fluorescence, positron emission tomography, single photon emission computed tomography, and magnetic resonance imaging and includes discussion of the advantages and disadvantages of each modality, and future directions for the design of diseaseC000718787 sensors. We also discuss the recent efforts focused on the design and development of multimodal sensors and the value of cross-validation across multiple modalities.
33454006		AggreCount: an unbiased image analysis tool for identifying and quantifying cellular aggregates in a spatially defined manner.Protein quality control is maintained by a number of integrated cellular pathways that monitor the folding and functionality of the cellular proteome. Defects in these pathways lead to the accumulation of misfolded or faulty proteins that may become insoluble and aggregate over time. Protein aggregates significantly contribute to the development of a number of 9606 diseases such as diseaseD000690, diseaseD006816, and diseaseD000544. In vitro, imaging-based, cellular studies have defined key biomolecular components that recognize and clear aggregates; however, no unifying method is available to quantify cellular aggregates, limiting our ability to reproducibly and accurately quantify these structures. Here we describe an ImageJ macro called AggreCount to identify and measure protein aggregates in cells. AggreCount is designed to be intuitive, easy to use, and customizable for different types of aggregates observed in cells. Minimal experience in coding is required to utilize the script. Based on a user-defined image, AggreCount will report a number of metrics: (i) total number of cellular aggregates, (ii) percentage of cells with aggregates, (iii) aggregates per cell, (iv) area of aggregates, and (v) localization of aggregates (cytosol, perinuclear, or nuclear). A data table of aggregate information on a per cell basis, as well as a summary table, is provided for further data analysis. We demonstrate the versatility of AggreCount by analyzing a number of different cellular aggregates including aggresomes, stress granules, and inclusion bodies caused by ncbi3064 polyglutamine expansion.
37562878		Advances in the neuroimaging of diseaseD000068079.Neuroimaging is a valuable adjunct to the history and examination in the evaluation of diseaseD016472. Conventional imaging with computed tomography or magnetic resonance imaging depicts important anatomic information and helps to identify imaging patterns which may support diagnosis of a specific diseaseD000068079. Advanced imaging techniques can provide further detail regarding volume, functional, or metabolic changes occurring in nervous system pathology. This chapter is an overview of the advances in neuroimaging with particular emphasis on both standard and less well-known advanced imaging techniques and findings, such as diffusion tensor imaging or volumetric studies, and their application to specific diseaseD000068079. In addition, it provides reference to emerging imaging biomarkers in diseaseD016472 such as diseaseD010300, diseaseD000690, and diseaseD006816, and briefly reviews the neuroimaging findings in different causes of diseaseD013118 and diseaseD010523.
34661664	Negative_Correlation|chemicalC000609690|diseaseD004409; Negative_Correlation|chemicalC000609690|diseaseD020323; Negative_Correlation|chemicalC000609690|diseaseD002819; Negative_Correlation|chemicalC000609690|diseaseD006816; Negative_Correlation|chemicalC000609690|diseaseD005879	Efficacy and Safety of Fixed-Dose chemicalC000609690 in Children and Adolescents for diseaseD020323 Associated With diseaseD005879: A Randomized Clinical Trial.Importance: diseaseD005879 is a diseaseD002658 characterized by childhood onset of diseaseD020323, often accompanied by behavioral and diseaseD001523 comorbidities. chemicalC000609690 is a vesicular monoamine transporter 2 inhibitor approved in the US for the treatment of diseaseD002819 associated with diseaseD006816 and diseaseD004409. Objective: To report results of the ARTISTS 2 (Alternatives for Reducing diseaseD020323 in diseaseD005879 2) study examining chemicalC000609690 for treatment of diseaseD005879. Design, Setting, and Participants: This phase 3, randomized, double-blind, placebo-controlled, parallel-group, fixed-dose study was conducted over 8 weeks with a 1-week follow-up (June 21, 2018, to December 9, 2019). Children and adolescents aged 6 to 16 years with a diagnosis of diseaseD005879 and active diseaseD020323 causing distress or impairment were enrolled in the study. Children were recruited from 52 sites in 10 countries. Data were analyzed from February 4 to April 22, 2020. Interventions: Participants were randomized (1:1:1) to low-dose chemicalC000609690 (up to 36 mg/d), high-dose chemicalC000609690 (up to 48 mg/d), or a matching placebo, which were titrated over 4 weeks to the target dose followed by a 4-week maintenance period. Main Outcomes and Measures: The primary efficacy end point was change from baseline to week 8 in the Yale Global diseaseD020323 Severity Scale-Total diseaseD020323 Score (YGTSS-TTS) for high-dose chemicalC000609690. Key secondary end points included changes in YGTSS-TTS for low-dose chemicalC000609690, diseaseD005879 Clinical Global Impression score, diseaseD005879 9606 Global Impression of Impact score, and 9606 and Adolescent diseaseD005879-Quality of Life Activities of Daily Living subscale score. Safety assessments included incidence of treatment-emergent adverse events, laboratory parameters, vital signs, and questionnaires. Results: The study included 158 children and adolescents (mean [SD] age, 11.7 [2.6] years). A total of 119 participants (75%) were boys; 7 (4%), Asian; 1 (1%), Black; 32 (20%), Hispanic; 4 (3%), Native American; 135 (85%), White; 2 (1%), multiracial; 9 (6%), other race; and 1 (0.6%), of unknown ethnic origin. Fifty-two participants were randomized to the high-dose chemicalC000609690 group, 54 to the low-dose chemicalC000609690 group, and 52 to the placebo group. Baseline characteristics for participants were similar between groups. Of the total 158 participants, 64 (41%) were aged 6 to 11 years, and 94 (59%) were aged 12 to 16 years at baseline. Mean time since diseaseD005879 diagnosis was 3.3 (2.8) years, and mean baseline YGTSS-TTS was 33.8 (6.6) points. At week 8, the difference in YGTSS-TTS was not significant between the high-dose chemicalC000609690 and placebo groups (least-squares mean difference, -0.8 points; 95% CI, -3.9 to 2.3 points; P = .60; Cohen d, -0.11). There were no nominally significant differences between groups for key secondary end points. Treatment-emergent adverse events were reported for 34 participants (65%) treated with high-dose chemicalC000609690, 24 (44%) treated with low-dose chemicalC000609690, and 25 (49%) treated with placebo and were generally mild or moderate. Conclusions and Relevance: In this fixed-dose randomized clinical trial of chemicalC000609690 in children and adolescents with diseaseD005879, the primary efficacy end point was not met. No new safety signals were identified. Trial Registration: ClinicalTrials.gov Identifier: NCT03571256.
33591252		[diseaseD006816: diseaseD019636 rooted in brain development?]
35771295		diseaseD006816 and neurovascular structure of retina.BACKGROUND: Retinal biomarkers in diseaseD019636 have attracted much attention in recent years. Recent studies have reported diseaseD014786 in diseaseD006816 (diseaseD006816). However, little is known about retinal structural changes in diseaseD006816. METHODS: A total of 50 subjects, including 25 motor-manifest diseaseD006816 9606 and 25 gender- and age-matched controls, were enrolled. Unified diseaseD006816 Rating Score-Motor part was assessed in diseaseD006816 9606. Spectral-domain Optical Coherence Tomography (SD-OCT) was used to evaluate the macular thickness and peripapillary retinal nerve fiber layer (pRNFL). Superficial and deep capillary plexus densities were measured using OCT angiography (OCTA). To account for inter-eye correlation, generalized estimating equation (GEE) model was used. RESULTS: diseaseD006816 9606 had a significant reduction in macular thickness in both inner and outer superior sectors and the diseaseD056989 outer sector. diseaseD056989 pRNFLs were significantly decreased in thickness. There was no significant difference in retinal capillary plexus density between the two groups. Age and disease duration were negatively correlated with macular thickness in diseaseD006816 9606. However, the severity of motor involvement was not correlated with SD-OCT or OCTA parameters. CONCLUSIONS: We observed attenuated pRNFL and macular retinal thickness in 9606 with diseaseD006816, independent of macular capillary plexus parameters. It can support the hypothesis that the retina may be a potential biomarker for monitoring the neurodegenerative process in diseaseD006816.
32370961	Association|chemicalD007501|diseaseD019636	ACR Appropriateness Criteria  diseaseD009069 and diseaseD019636.diseaseD009069 and diseaseD019636 are a variety of conditions that involve progressive diseaseD009410, or diseaseD003643. Establishing the correct diagnosis of a diseaseD009069 or diseaseD019636 can be difficult due to the variable features of these conditions, unusual clinical presentations, and overlapping symptoms and characteristics. MRI has an important role in the initial assessment of these 9606, although a combination of imaging and laboratory and genetic tests is often needed for complete evaluation and management. This document summarizes the imaging appropriateness data for rapidly progressive diseaseD003704, diseaseD002819, diseaseD020734, suspected diseaseD019636 with brain chemicalD007501 accumulation, and suspected diseaseD016472. The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed annually by a multidisciplinary expert panel. The guideline development and revision include an extensive analysis of current medical literature from peer reviewed journals and the application of well-established methodologies (RAND/UCLA Appropriateness Method and Grading of Recommendations Assessment, Development, and Evaluation or GRADE) to rate the appropriateness of imaging and treatment procedures for specific clinical scenarios. In those instances where evidence is lacking or equivocal, expert opinion may supplement the available evidence to recommend imaging or treatment.
35618981		Recent Synergy of Nanodiamonds: Role in Brain-Targeted Drug Delivery for the Management of diseaseD009461.The aim of the present review article is to summarize the role of nanodiamonds in various diseaseD020271. We have taken related literature of making this review article from ScienceDirect, springer, Research gate, PubMed, Sci-finder, etc. The current approaches for treating diseaseD019636 such as diseaseD005909 includes chemotherapy or combination anti-retro viral therapy for 12721 (12721) or use of anti-diseaseD000544 drugs during diseaseD003072. These approaches can provide only symptomatic relief as they do not target the cause of the disease due to their inability to penetrate the blood brain barrier. On long-term use, they may cause diseaseD002493 due to accumulation in the brain. So nanodiamonds could prove as a promising approach in the brain targeting of the bioactive and to treat many diseaseD009461 such as diseaseD000544, diseaseD010300, diseaseD001932 (diseaseD005909), diseaseD015658, diseaseD009103, diseaseD006816, diseaseD020521 (diseaseD002561), diseaseD009472, diseaseD012559, diseaseD004827, and diseaseD001424 (diseaseD004660, diseaseD018805, and diseaseD008580) due to their ability to penetrate the blood-brain barrier and owing to their excellent surface properties, i.e., nano size and high surface area, ease of functionalization, multiple drug binding, and biocompatibility; they can be useful for brain targeted drug delivery with minimal side effects.
34697770	Negative_Correlation|chemicalD014212|diseaseD019636; Negative_Correlation|chemicalD003474|diseaseD019636; Positive_Correlation|chemicalD001599|diseaseC537849; Negative_Correlation|chemicalC043561|diseaseD019636; Negative_Correlation|chemicalD000077185|diseaseD019636; Positive_Correlation|chemicalC004999|diseaseC537849; Positive_Correlation|chemicalC050426|diseaseC537849; Positive_Correlation|chemicalC043561|diseaseC537849; Positive_Correlation|chemicalD014212|diseaseC537849; Negative_Correlation|chemicalC013015|diseaseD019636; Negative_Correlation|chemicalD011794|diseaseD019636; Positive_Correlation|chemicalD000077185|diseaseC537849; Positive_Correlation|chemicalC006680|diseaseC537849; Association|chemicalD017382|diseaseC537849; Negative_Correlation|chemicalC004999|diseaseD019636; Negative_Correlation|chemicalD001599|diseaseD019636; Positive_Correlation|chemicalD003474|diseaseC537849; Positive_Correlation|chemicalD011794|diseaseC537849; Positive_Correlation|chemicalC008922|diseaseC537849; Negative_Correlation|chemicalC008922|diseaseD019636; Negative_Correlation|chemicalC006680|diseaseD019636; Negative_Correlation|chemicalC050426|diseaseD019636; Positive_Correlation|chemicalC013015|diseaseC537849	Emerging Novel Approaches for the Enhanced Delivery of Natural Products for the Management of diseaseD019636.diseaseD019636 (diseaseD019636) such as diseaseD000544, diseaseD010300, diseaseD006816, diseaseD000690, and diseaseD017096 affect any part of the brain. The complete mechanism of diseaseC537849 is unknown, but there are some molecular mechanism and chemical process. Natural compounds have better compatibility with the 9606 body along with lesser side effects. Moreover, several studies showed that various natural compounds have significant neuroprotective, potent antioxidant, and anti-diseaseD007249 properties, which are effective for treating the different type of diseaseC537849. In diseaseC537849, natural compounds act by various mechanisms such as preventing the generation of chemicalD017382 (chemicalD017382), eliminating destructed biomolecules before their accumulation affects cell metabolism, and improving the disease conditions. But due to the presence of the blood-brain barrier (BBB) layer and unfavorable pharmacokinetic properties of natural compounds, their delivery into the brain is limited. To minimize this problem and enhance drug delivery into the brain with an effective therapeutic dose, there is a need to develop a practical novel approach. The various studies showed that nanoformulations and microneedles (MN) containing natural compounds such as chemicalD011794, chemicalD003474, chemicalD000077185, chemicalC043561, chemicalC008922, chemicalC004999, chemicalC050426, chemicalD001599, chemicalC006680, chemicalC013015, and chemicalD014212 effectively improved many diseaseC537849. In this review, the effect of such natural drug-loaded nanoformulation and MN patches on diseaseC537849 management is discussed, along with their merits and demerits. This review aims to introduce different novel approaches for enhancing natural drug delivery into the brain to manage various diseaseD019636.
34077591		Clinical predictors and neural correlates for compromised swallowing safety in diseaseD006816.BACKGROUND AND PURPOSE: diseaseD003680 is one of the most common and important complications in diseaseD006816 (diseaseD006816), frequently leading to diseaseD011015 and mortality. Objective estimates of prevalence using instrumental diagnostics and data on neural correlates of diseaseD003680 in diseaseD006816 are scarce or lacking entirely. Similarly, its correlation with other clinical markers is still not fully known. We aimed at defining clinical risk factors and neural correlates for compromised swallowing safety in diseaseD006816 more precisely. METHODS: Thirty-four diseaseD006816 subjects (16 female, Shoulson & Fahn Stage I-IV, two premanifest) underwent a full clinical-neurological examination including the cranial nerves, the Unified diseaseD006816 Rating Scale total motor score, and the Mini-Mental State Examination. Fiberoptic endoscopic evaluation of swallowing (FEES) was performed by a trained speech and language therapist. Twenty-six subjects additionally underwent a high-resolution anatomical magnetic resonance imaging (MRI) scan (T1, 3-T Siemens Prisma). Moreover, we correlated clinical and diseaseD001284 (MRI) measures with swallowing safety levels as judged by the validated Penetration-Aspiration Scale. RESULTS: FEES showed penetration or aspiration in 70.6%. Using partial correlation, no significant correlations were found between swallowing safety and any of the clinical markers after correcting for disease duration and CAG repeat length. Voxel-based morphometry demonstrated diseaseD001284 associated with compromised swallowing safety in a network of parietothalamocerebellar areas related to sensorimotor communication, notably excluding striatum. CONCLUSIONS: Our results characterise diseaseD003680 in diseaseD006816 as a disorder of communication between sensory and motor networks involved in swallowing. This finding and high rates of silent aspiration argue in favor of instrumental swallowing evaluation early in the disease.
33856270	Negative_Correlation|chemicalC005273|diseaseD009461; Positive_Correlation|chemicalC015392|diseaseD009461; Negative_Correlation|chemicalC005273|diseaseD019954; Positive_Correlation|chemicalC005273|ncbi29253; Negative_Correlation|chemicalC005273|chemicalC015392; Negative_Correlation|chemicalC005273|diseaseD006816; Positive_Correlation|chemicalC015392|diseaseD006816; Negative_Correlation|chemicalC005273|diseaseD019636; Negative_Correlation|chemicalC005273|diseaseD007249; Positive_Correlation|chemicalC005273|chemicalD012701; Negative_Correlation|chemicalC005273|ncbi24387	chemicalC005273 mitigates behavioral alterations and provides neuroprotection against 3-nitropropinoic acid-induced diseaseD006816 like symptoms in 10116.BACKGROUND: chemicalC005273 is a powerful antioxidant and anti-diseaseD007249 chemicalD005419 which has been widely used as a therapeutic agent in various toxic models. However, few studies have clearly discussed the neuromodulatory effects of chemicalC005273 against different diseaseD019636. AIM: We investigated the neuroprotective efficacy of chemicalC005273 against chemicalC015392 (chemicalC015392)-induced neurobehavioral, biochemical and histopathological alterations in 10116. METHODS: Albino Wistar 10116 were randomly divided into three experimental groups. Group 1, the vehicle administered group, received saline. Group 2 received chemicalC015392 (20 mg/kg body weight, i.p.) for 4 consecutive days. Group 3 received chemicalC005273 (50 mg/kg body weight, p.o.) twice daily for a period of 4 days, 30 min before and 6 h after the chemicalC015392 administration. On the 5th day, neurobehavioral experiments were performed to access the behavioral outcomes and the striatum tissue was used for analysis of the ncbi29253 (ncbi29253) activity and chemicalD012701 (chemicalD012701) levels. In addition, astrocytes activation was observed by ncbi24387 (ncbi24387) immunostaining. RESULTS: Our results showed that chemicalC005273 co-treatment provides neuroprotection against chemicalC015392-induced diseaseD009461. chemicalC005273 also increased the ncbi29253 activity and chemicalD012701 levels in the striatum. Moreover, co-treatment with chemicalC005273 reduced the expression of ncbi24387 protein in the striatal part and significantly attenuated the neuronal cell death. The findings of the present study suggest that chemicalC005273 provides neuroprotection and mitigates diseaseD019954 in experimental 10116. CONCLUSION: The results show that co-treatment with chemicalC005273 ameliorates chemicalC015392-induced diseaseD006816-like symptoms in 10116.
38263475		[Retinal OCT biomarkers and diseaseD019636 of the central nervous system beyond diseaseD000544].BACKGROUND: Optical coherence tomography (OCT) biomarkers are increasingly used by neurologists, psychiatrists, and ophthalmologists for the diagnosis, prognosis, and follow-up of diseaseD019636. Long-term data on OCT biomarkers of selected primary and secondary diseaseD019636 of the central nervous system (CNS), such as diseaseD009103 (diseaseD009103) or diseaseD010300, are already available in part. In addition, there are rare diseaseD019636 with early disease onset that may show diseaseC537669. METHODS: A literature review on the association of OCT biomarkers with diseaseD019636 of the CNS beyond diseaseD000544 is presented. diseaseD010300, diseaseD009103, diseaseD005621, diseaseD006816, diseaseD020754, and diseaseD016464 are addressed. RESULTS: Relevant OCT biomarkers of diseaseD019636 are the macular ganglion cell inner plexiform layer (GCIPL) and the peripapillary retinal nerve fiber layer (pRNFL) thickness. Different sectors may be affected depending on the disease entity in addition to global pRFNL reduction. OCT-angiography (OCT-A) is also increasingly used as a biomarker in diseaseD019636. CONCLUSION: Optical coherence tomography biomarkers are used in an interdisciplinary context. diseaseD012164 should be excluded by an ophthalmologist. While OCT biomarkers are increasingly used clinically in diseaseD009103, the benefit in other diseaseD019636, especially the rare ones, is less well documented. Further longitudinal studies are required.
34291654		Disparities in Palliative Care Utilization Among Hospitalized 9606 With diseaseD006816: A National Cross-Sectional Study.BACKGROUND: 9606 with diseaseD006816 (diseaseD006816) often become institutionalized and more frequently die away from the home setting. The reasons behind differences in end-of-life care are poorly understood. Less than 5% of 9606 with diseaseD006816 report utilization of palliative care (PC) or hospice services, regardless of the lack of curative therapies for this diseaseD019636. It is unknown what factors are associated with in-9606 specialty PC consultation in this population and how PC might be related to discharge disposition. OBJECTIVES: To determine what diseaseD006816-specific (e.g., diseaseD011618) and serious illness-specific factors (e.g., resuscitation preferences) are associated with PC encounters in 9606 with diseaseD006816 and explore how PC encounters are associated with discharge disposition. DESIGN: We analyzed factors associated with PC consultation for 9606 with diseaseD006816 using discharge data from the National Inpatient Sample and the Nationwide Inpatient Sample (NIS), Healthcare Cost and Utilization Project (HCUP), Agency for Healthcare Research and Quality. An anonymized, cross-sectional, and stratified sample of 20% of United States hospitalizations from 2007 through 2014 were included using ICD-9 codes. RESULTS: 8521 9606 with diseaseD006816 were admitted to the hospital. Of those, 321 (3.8%) received specialty PC. Payer type, (specifically private insurer or other insurer as compared to Medicare), income, (specifically the top quartile as compared to the bottom quartile), mortality risk, D.N.R., diseaseD011015, and diseaseD003866 were significantly associated with PC in a multivariate model. Among those who received PC, the odds ratio (OR) of discharge to a facility was 0.43 (95% CI, 0.32-0.58), whereas the OR of discharge to home with services was 2.25 (95% CI 1.57-3.23), even after adjusting for possible confounders. CONCLUSIONS: Among 9606 with diseaseD006816, economic factors, diseaseD003866, and serious illness-specific factors were associated with PC, and PC was associated with discharge disposition. These findings have implications for the adaptation of inpatient PC models to meet the needs of 9606 with diseaseD006816.
35698434		Does physical activity improve motor function and gait in diseaseD006816? A systematic review and meta-analysis.INTRODUCTION: diseaseD006816 (diseaseD006816) is a diseaseD001927. OBJECTIVE: To assess the evidence of the physical activity (PA) to improve motor function, gait speed, and walking endurance in individuals with diseaseD006816. MATERIALS AND METHODS: Two reviewers independently screened references and selected relevant studies to identify randomized controlled trials (RCT), from MEDLINE/PubMed, CENTRAL, PEDro, Scopus, CINAHL, Web of Science databases from inception to September 2021. Two reviewers evaluated risk of bias by the PEDro scale. The primary outcome was assessed motor function, gait speed and walking endurance as a secondary outcome was evaluated activities of daily living (ADL), lower limb functionality strenght, balance, mobility and cognition function in diseaseD006816. RESULTS: Eight RCT were finally included (231 individuals). Forest plots showed a positive effect for gait endurance, the mean difference (MD) was 17.40 (95% CI from 5.40 to 29.35; p = 0.004), the MD lower limb functionality strength was 1.76 (95% CI from 0.18 to 3.33; p = 0.03) favoring PA group and the MD cognition function was 1.83 (95% CI from 0.50 to 3.16; p = 0.007). No benefits were found for motor function, gait speed, ADL, balance and mobility. CONCLUSIONS: Positive effects of programs PA were observed for walking endurance lower limb functionality strenght and cognition function in low and moderate stage of diseaseD006816. However, no benefits were found for motor function, gait speed, ADL, balance and mobility. All authors included aerobic exercises in their programs but is unclear if vigorous and intensive PA is optimal for individuals with diseaseD006816.
34531262	Association|diseaseD006816|ncbi9900; Negative_Correlation|chemicalC000618323|ncbi64051; Association|diseaseD003704|ncbi9900; Association|chemicalC000618323|diseaseD006816; Association|diseaseD006816|ncbi64051	ncbi64051 Is Affected in the Central Nervous System of 10090 with diseaseD006816 and in the Brain of a 9606 with diseaseD006816 Postmortem.diseaseC536122 is a primary mechanism underlying diseaseD006816 (diseaseD006816) progression. This study investigated changes in ncbi9900 (ncbi9900) density by means of chemicalC000618323 small-animal PET imaging in the central nervous system of 10090 with diseaseD006816. Methods: Dynamic chemicalC000618323 small-animal PET imaging was performed at clinically relevant disease stages (at 3, 7, 10, and 16 mo) in the heterozygous knock-in Q175DN 10090 model of diseaseD006816 and wild-type littermates (16-18 10090 per genotype and time point). Cerebral chemicalC000618323 analyses were performed to assess genotypic differences during presymptomatic (3 mo) and symptomatic (7-16 mo) disease stages. chemicalC000618323 binding in the spinal cord was quantified at 16 mo. 3H-UCB-J autoradiography and ncbi9900 immunofluorescence were performed postmortem in 10090 and 9606 brain tissues. Results:chemicalC000618323 binding was lower in symptomatic heterozygous 10090 than in wild-type littermates in parallel with disease progression (7 and 10 mo: P < 0.01; 16 mo: P < 0.0001). Specific chemicalC000618323 binding was detectable in the spinal cord, with symptomatic heterozygous 10090 displaying a significant reduction (P < 0.0001). 3H-UCB-J autoradiography and ncbi64051 immunofluorescence corroborated the in vivo measurements demonstrating lower ncbi64051 in heterozygous 10090 (P < 0.05). Finally, preliminary analysis of ncbi9900 in the 9606 brain postmortem suggested lower ncbi9900 in diseaseD006816 gene carriers than in controls without diseaseD003704. Conclusion:chemicalC000618323 PET detected ncbi64051 deficits during symptomatic disease in heterozygous 10090 in both the brain and the spinal cord and therefore may be suitable as a novel marker of synaptic integrity widely distributed in the central nervous system. On clinical application, chemicalC000618323 PET imaging may have promise for ncbi9900 measurement in 9606 with diseaseD006816 during disease progression and after disease-modifying therapeutic strategies.
32794251		Connections between the internal and the external capsules and the globus pallidus in the 9940: A dichromate stain X-ray microtomographic study.9940 are recognized as useful species for translational diseaseD019636 research, in particular for the study of diseaseD006816. There is a lack of information regarding the detailed anatomy and connections of the basal ganglia of 9940, in normal myeloarchitectonics and in tract-tracing studies. In this work, the organization of the corticostriatal projections at the level of the putamen and globus pallidus (GP) are explored. For the first time, the myeloarchitectonic pattern of connections between the internal (IC) and the external (EC) capsules with the GP have been investigated in the 9940. chemicalD005557-fixed blocks of the striatum were treated with a metallic stain containing chemicalD011192 and visualized using micro-CT (micro-CT). The trivalent chromium (Cr3+), attached to myelin chemicalD010743, imparts a differential contrast to the grey and white matter compartments, which allows the visualization of myelinated fascicles in micro-CT images. The fascicles were classified according to their topographical location in dorsal supreme fascicles (X, Y, apex) arising from the IC and EC; pre-commissurally, basal fascicles connecting the ventral part of the EC with the lateral zone of the ventral pallidum (VP) and, post-commissurally, superior (Z1 ), middle (Z2 ) and lower (Z3 ) fascicles, connecting at different levels the EC with the GP. The results suggest that the presumptive cortical efferent and afferent fibres to the pallidum could be organized according to a dorsal to ventrolateral topography in the 9940, similar to that seen in other mammals. The proposed methodology has the potential to delineate the myeloarchitectonic patterns of nervous systems and tracts.
36429634		Home-Based Exercise to Improve Motor Functions, Cognitive Functions, and Quality of Life in People with diseaseD006816: A Systematic Review and Meta-Analysis.Exercise in different settings has become a fundamental part of diseaseD006816 (diseaseD006816) management. The aim of this systematic review and meta-analysis was to investigate the effectiveness of home-based exercises (HBE) in diseaseD006816. Randomized controlled trials (RCTs) investigating the effect of HBE on motor, cognitive, or health-related quality of life (QoL) outcomes in diseaseD006816 were included. Standardized mean difference (SMD), the 95% confidence interval, and p-values were calculated by comparing the outcomes change between HBE and control groups. Seven RCTs met the inclusion criteria. The included RCTs prescribed different types of HBEs, i.e., aerobic strengthening, walking, balance, and fine motor exercises. The HBE protocol length was between 6 and 36 weeks. The meta-analyses showed a significant effect of HBE intervention on motor function measure by Unified diseaseD006816 Rating and overall QoL measure by Short Form-36 post-treatment respectively, [SMD = 0.481, p = 0.048], [SMD = 0.378, p = 0.003]. The pooled analysis did not detect significant changes in cognition, gait characteristics, or functional balance scales. The current study shows the positive effect of HBE in diseaseD006816, especially on motor function and QoL. No significant adverse events were reported. The current results support the clinical effect of HBE intervention on motor function and QoL in diseaseD006816 9606. However, these results should be taken with caution due to the limited available evidence. Well-designed clinical studies that consider the disease severity and stages are required in the future.
34543681	Positive_Correlation|chemicalD008345|diseaseD009422; Positive_Correlation|chemicalD008345|diseaseD020258	2244 10090 model of diseaseD006816 is protected against subtle chronic chemicalD008345 (Mn)-induced behavioral and diseaseD009422 changes.chemicalD008345 (Mn) is an essential micronutrient but excessive levels induce diseaseD020258. Increasing evidence suggests a deficit of bioavailable Mn in diseaseD006816 (diseaseD006816), an diseaseD020271 characterized by diseaseD003072. Previous studies have shown rescue of some molecular diseaseD006816 phenotypes by acute Mn exposure. This study simultaneously examined the potential for chronic Mn exposure to attenuate diseaseD006816 behavioral phenotypes, and for the diseaseD006816 genotype to offer protection against detrimental effects of chronic Mn exposure. In two independent studies a chronic Mn exposure paradigm was implemented in the 2244 10090 model of diseaseD006816 and behavior was assessed at several timepoints. Study 1 exposed WT and 2244 10090 to twice weekly subcutaneous injections of 0, 5, 15, or 50 mg/kg MnCl[2] tetrahydrate from 12 to 32 weeks of age. A promising protective effect against diseaseD001259 in 5 mg/kg MnCl[2] tetrahydrate-treated 2244 10090 was detected. Study 2 thus exposed WT and 2244 10090 to either 0 or 5 mg/kg MnCl[2] tetrahydrate from 12 to 52 weeks of age (with a partial randomized treatment crossover at 31 weeks). The same protective effect was not observed under these conditions at higher statistical power. We report subtle toxicological changes in exploratory behavior and total activity induced by chronic Mn exposure in WT 10090 only, despite similar total increases in brain Mn in WT and 2244 10090. Further, chronic Mn treatment resulted in a 10-12 % decrease in striatal ncbi52897 positive cell density in WT 10090 but not 2244 10090, despite vehicle cell counts already being reduced compared to WT 10090 as expected for the diseaseD006816 genotype. The subtle changes observed in specific outcome measures, but not others, following long-term low-level Mn exposure in WT 10090 delineate the neurobehavioral and diseaseD009422 effects at the threshold of chronic diseaseD020149. We conclude that these chronic low-dose Mn exposures do not significantly rescue behavioral diseaseD006816 phenotypes, but YAC2128 10090 are protected against the subtle Mn-induced behavioral changes and decreased striatal neuron density observed in Mn-exposed WT 10090.
33377823		diseaseD006816 in Turkey: genetic counseling, clinical features, and outcome.Objective: This study aims to report the data of genetic counseling and to identify the clinical features of Turkish diseaseD006816 (diseaseD006816) 9606 and to investigate its possible relationship with genetic data.Method: A regular weekly 9606 clinic has been held routinely since January 2018. 9606 and their referred relatives have been evaluated regarding clinical features and genetic counseling. The database of our collaborative team was used for the study.Results: Total 141 individuals have been evaluated. Among 84 subjects genetic counseling was given, diagnosis of diseaseD006816 was confirmed genetically in 34 (42.0%) of individuals (25 were symptomatic-diseaseD006816, 9 were presymptomatic-diseaseD006816). Fifty-seven 9606 were previously diagnosed with diseaseD006816. The mean age of onset was 42.4 (11.9) years. diseaseD002819 was mostly reported initial symptom. The mean CAG repeat number of the expanded allele was 44.1 (5.1) and correlated inversely with the age of onset (p < 0.001). During a 4.8 (3.1) year follow-up, 10% of the 9606 were deceased. At the last visit, over half of 9606 had all of the diseaseD003072, and 41.6% of them had required 24-hr supervision appropriate (UHDRS-independence score 64.6 (24.4)). Paternal inheritance was related to higher CAG repeats, younger age of disease onset, and higher UHDRS-motor scores.Conclusion: diseaseD006816 in Turkey is a severe disabling disease affecting a younger adult population. Over half of 9606 had all of the diseaseD003072. Genetic counseling gives the opportunity to diagnose subjects at the pre-symptomatic phase. A collaborative approach is rational in the management of diseaseD006816.
32775019	Association|diseaseD006816|ncbi203228	Screening for the ncbi203228 expansion in Greek diseaseD006816 phenocopies and controls and meta-analysis of current data.Background: Several European studies examined the role of ncbi203228 repeat expansion in 9606 with diseaseD006816 like phenotypes (diseaseD006816-L). The scope of our study is to investigate the expansion frequency in a Greek diseaseD006816-L cohort and the meta-analysis of all published cases. This will be of use in genetic counseling of these cases. Methods: A cohort of 74 9606 with diseaseD006816-L and 67 healthy controls were screened for the ncbi203228 expansion status. Case-controls comparison was assessed with the Pearson's chi-square statistic for a 2 x 2 table.A systematic database search was conducted and seven studies, including the current study, were considered eligible for inclusion in a meta-analysis considering a total of 812 9606 with diseaseD006816 phenocopies. Pooled mutation frequency was calculated using a Random Effects model or the Mantel-Haezsel fixed effects model, depending on the observed heterogeneity. Results: In our cohort, one 9606 was found to have a pathologic expansion of ncbi203228, and none from the control group (chi-square: 0.91, p-value: 0.34). Pooled mutation frequency was found at 2% (CI: 1-3%) with low heterogeneity (I2:15%). Discussion: Based on this meta-analysis the recommendation for genetic testing for ncbi203228 expansions is further solidified.
33571915		diseaseD021081 as an early pathologic feature of diseaseD006816.OBJECTIVE: diseaseD001342 has been described in adults with motor-manifest diseaseD006816 (diseaseD006816) or those who are near their predicted motor onset. It is unclear if diseaseD001342 is present years prior to the onset of motor symptoms of diseaseD006816. To bridge this gap in knowledge, we compared crude markers of ANS function between children with the gene-expansion that causes diseaseD006816 (GE group) who were decades from their predicted motor onset and gene-non-expanded children (GNE group). METHODS: We included participants from the Kids-diseaseD006816 study who were <18 years old. Linear mixed effects regression models were constructed that controlled for sex, age, and BMI, and included a random effect per 9606 and per family. We compared resting heart rate (rHR), core body temperature (CBT), systolic blood pressure (SBP), and diastolic blood pressure (DBP) between the GE (n = 84) and GNE (n = 238) groups. We then grouped participants from the GE group based on their predicted years to onset (YTO) and compared their vital signs to the GNE group. RESULTS: The GE group had higher rHR (  = 3.83, p = 0.0064), SBP (  = 2.38, p = 0.032), and CBT (  = 0.16, t = 2.92, p = 0.007). The mean rHR and CBT became significantly elevated compared to the GNE group in participants who had 15-25 YTO and those who had <15 YTO. The mean SBP of participants who had 25-35 YTO was significantly elevated compared to the GNE group. CONCLUSION: diseaseD001342 in diseaseD006816 seems to occur approximately 20 years prior to the predicted onset of motor symptoms of diseaseD006816.
32700226		Optical coherence tomography angiography findings in diseaseD006816.OBJECTIVES: To evaluate the retinal and choriocapillaris vascular networks in macular region and the central choroidal thickness (CCT) in 9606 affected by diseaseD006816 (diseaseD006816), using optical coherence tomography angiography (OCTA) and enhanced depth imaging spectral-domain OCT (EDI SD-OCT). METHODS: We assessed the vessel density (VD) in superficial capillary plexus (SCP), deep capillary plexus (DCP), and choriocapillaris (CC) using OCTA, while CCT was measured by EDI SD-OCT. RESULTS: Sixteen diseaseD006816 9606 (32 eyes) and thirteen healthy controls (26 eyes) were enrolled in this prospective study. No significant difference in retinal and choriocapillaris VD was found between diseaseD006816 9606 and controls while CCT turned to be thinner in 9606 respect to controls. There were no significant relationships between OCTA findings and neurological parameters. CONCLUSION: The changes in choroidal structure provide useful information regarding the possible neurovascular involvement in the physiopathology of diseaseD006816. Choroidal vascular network could be a useful parameter to evaluate the diseaseD020141 that occurs in this diseaseD019636.
36409538		Digital Devices for Assessing Motor Functions in diseaseD014086 and Healthy Populations: Systematic Literature Review.BACKGROUND: With the advent of smart sensing technology, mobile and wearable devices can provide continuous and objective monitoring and assessment of motor function outcomes. OBJECTIVE: We aimed to describe the existing scientific literature on wearable and mobile technologies that are being used or tested for assessing motor functions in diseaseD014086 and healthy adults and to evaluate the degree to which these devices provide clinically valid measures of motor function in these populations. METHODS: A systematic literature review was conducted by searching Embase, MEDLINE, CENTRAL (January 1, 2015, to June 24, 2020), the United States and European Union clinical trial registries, and the United States Food and Drug Administration website using predefined study selection criteria. Study selection, data extraction, and quality assessment were performed by 2 independent reviewers. RESULTS: A total of 91 publications representing 87 unique studies were included. The most represented clinical conditions were diseaseD010300 (n=51 studies), followed by diseaseD020521 (n=5), diseaseD006816 (n=5), and diseaseD009103 (n=2). A total of 42 motion-detecting devices were identified, and the majority (n=27, 64%) were created for the purpose of health care-related data collection, although approximately 25% were personal electronic devices (eg, smartphones and watches) and 11% were entertainment consoles (eg, Microsoft Kinect or Xbox and Nintendo Wii). The primary motion outcomes were related to gait (n=30), gross motor movements (n=25), and fine motor movements (n=23). As a group, sensor-derived motion data showed a mean sensitivity of 0.83 (SD 7.27), a mean specificity of 0.84 (SD 15.40), a mean accuracy of 0.90 (SD 5.87) in discriminating between diseased individuals and healthy controls, and a mean Pearson r validity coefficient of 0.52 (SD 0.22) relative to clinical measures. We did not find significant differences in the degree of validity between in-laboratory and at-home sensor-based assessments nor between device class (ie, health care-related device, personal electronic devices, and entertainment consoles). CONCLUSIONS: Sensor-derived motion data can be leveraged to classify and quantify disease status for a variety of neurological conditions. However, most of the recent research on digital clinical measures is derived from proof-of-concept studies with considerable variation in methodological approaches, and much of the reviewed literature has focused on clinical validation, with less than one-quarter of the studies performing analytical validation. Overall, future research is crucially needed to further consolidate that sensor-derived motion data may lead to the development of robust and transformative digital measurements intended to predict, diagnose, and quantify diseaseD020271 state and its longitudinal change.
32590293	Association|diseaseD001007|ncbi15194; Association|ncbi18429|ncbi551; Association|diseaseD006816|ncbi15194; Association|diseaseC000631768|ncbi18429; Association|diseaseD003866|ncbi18429; Association|diseaseD006816|ncbi18429; Association|diseaseC000631768|ncbi551; Negative_Correlation|diseaseD006816|ncbi5020; Negative_Correlation|diseaseD006816|ncbi551	Imbalance of the ncbi18429-ncbi551 system contributes to the diseaseC000631768 in the BACHD 10090 model of diseaseD006816.diseaseD001523 with altered social cognition, diseaseD003866 and diseaseD001007 are among the most debilitating early features in the fatal diseaseD019636 diseaseD006816 (diseaseD006816) which is caused by an expanded CAG repeat in the ncbi15194 gene. The underlying neurobiological mechanisms are not known. Neuropathological analyses of postmortem 9606 diseaseD006816 hypothalamic tissue have demonstrated loss of the neuropeptides ncbi5020 and ncbi551. The dynamic interplay between these neuropeptides is crucial for modulating emotional and social behavior but its role in diseaseD006816 is unclear. In the present study, we have investigated the effect of expressing the mutant ncbi15194 gene on the development of behavioral changes using the transgenic BACHD 10090 model at different ages. We show for the first time that BACHD 10090 exhibit deficits in social behavior with parallel aberrations in the balance of the ncbi18429-ncbi551 system. Importantly, our data also show that restoration of the interplay within the system with an acute dose of intranasal ncbi18429 immediately prior to behavioral testing can rescue the diseaseD003866-like phenotype but not diseaseD001007-like behavior in this transgenic model. These findings demonstrate that imbalances in the ncbi18429-ncbi551 interplay contribute to the neuropsychiatric component of diseaseD006816 and suggest that interventions aimed at restoring the blunted levels of ncbi18429 may confer therapeutic benefits for this disease.
32674730		Gene Therapy, A Novel Therapeutic Tool for diseaseD009461: Current Progress, Challenges and Future Prospective.diseaseD009461 are one of the major threat for health care system as they put enormous socioeconomic burden. All aged populations are susceptible to one or other diseaseD009461 with symptoms of diseaseD000090862, diseaseD019636 and diseaseD003072. At present, available pharmacotherapeutics are insufficient to treat these diseased conditions and in most cases, they provide only palliative effect. It was also found that the molecular etiology of diseaseD009461 is directly linked with the alteration in genetic makeup, which can be inherited or triggered by the injury, environmental toxins and by some existing disease. Therefore, to take care of this situation, gene therapy has emerged as an advanced modality that claims to permanently cure the disease by deletion, silencing or edition of faulty genes and by insertion of healthier genes. In this modality, vectors (viral and non-viral) are used to deliver targeted gene into a specific region of the brain via various routes. At present, gene therapy has shown positive outcomes in complex diseaseD009461, such as diseaseD010300, diseaseD000544, diseaseD006816, diseaseD009103, diseaseD000690 and in diseaseD016464. However, there are some limitations such as immunogenic reactions non-specificity of viral vectors and a lack of effective biomarkers to understand the efficacy of therapy. Considerable progress has been made to improve vector design, gene selection and targeted delivery. This review article deals with the current status of gene therapy in diseaseD009461 along with its clinical relevance, challenges and future prospective.
33749915		Reply to: "Cell Therapy for diseaseD006816: Learning from Failure".
33246883		Induced pluripotent stem cells derived from the developing striatum as a potential donor source for cell replacement therapy for diseaseD006816.BACKGROUND: Cell replacement therapy (CRT) for diseaseD006816 (diseaseD006816) requires a source of striatal (STR) progenitors capable of restoring the function lost due to diseaseC537500. Authentic STR progenitors can be collected from the fetal putative striatum, or whole ganglionic eminence (WGE), but these tissues remain impractical for widespread clinical application, and alternative donor sources are required. Here we begin exploring the possibility that induced pluripotent stem cells (iPSC) derived from WGE may retain an epigenetic memory of their tissue of origin, which could enhance their ability to differentiate into STR cells. RESULTS: We generate four iPSC lines from 9606 WGE (hWGE) and establish that they have a capacity similar to 9606 embryonic stem cells with regard to their ability to differentiate toward an STR phenotype, as measured by expression and demethylation of key STR genes, while maintaining an overall different methylome. Finally, we demonstrate that these STR-differentiated hWGE iPSCs share characteristics with hWGE (i.e., authentic STR tissues) both in vitro and following transplantation into an diseaseD006816 model. Overall, iPSCs derived from 9606 WGE show promise as a donor source for CRT for diseaseD006816.
37202171		Pearls and Oy-sters: diseaseD006816 Presenting as diseaseD018888: A Case of Semantics.We present a case of semantic variant diseaseD018888 (diseaseD018888) as the presenting feature in a 9606 with diseaseD006816 (diseaseD006816). The 9606 initially developed progressive diseaseD007806 including diseaseD014012 and single word comprehension and then developed diseaseD002819 and behavioural changes. Magnetic resonance imaging (MRI) of the brain showed left anterior temporal lobe and diseaseD001284. A neurological chemicalD019788 PET/CT showed reduced metabolism in the head of the left caudate nucleus. ncbi3064 gene testing revealed an expansion of 39 CAG repeats in one allele. This case outlines the substantial overlap between the clinical presentation of diseaseD006816 and diseaseD057174 and provides commentary on the investigation of these diseaseD019636.
33556538	Association|diseaseD006816|ncbi15194	Super-resolution imaging reveals extrastriatal synaptic dysfunction in presymptomatic diseaseD006816 10090.Synaptic structure and function are compromised prior to cell death and symptom onset in a variety of diseaseD019636. In diseaseD006816 (diseaseD006816), a CAG repeat expansion in the gene encoding the ncbi15194 protein results in a presymptomatic stage that typically spans multiple decades and is followed by striking degeneration of striatal tissue and the progression of debilitating motor symptoms. Many lines of evidence demonstrate that the diseaseD006816 presymptomatic window is associated with injurious effects to striatal synapses, many of which appear to be prerequisites to subsequent cell death. While the striatum is the most vulnerable region in the diseaseD006816 brain, it is widely recognized that diseaseD006816 is a brain-wide disease, affecting numerous extrastriatal regions that contribute to debilitating non-motor symptoms including diseaseD003072. Currently, we have a poor understanding of the synaptic integrity, or lack thereof, in extrastriatal regions in the presymptomatic diseaseD006816 brain. If early therapeutic intervention seeks to maintain healthy synaptic function, it is important to understand early diseaseD006816-associated synaptopathy at a brain-wide, rather than striatal-exclusive, level. Here, we focused on the hippocampus as this structure is generally thought to be affected only in manifest diseaseD006816 despite the subtle diseaseD003072 known to emerge in prodromal diseaseD006816. We used super-resolution microscopy and multi-electrode array electrophysiology as sensitive measures of excitatory synapse structure and function, respectively, in the hippocampus of presymptomatic heterozygous diseaseD006816 10090 (Q175FDN model). We found clear evidence for enhanced AMPA receptor subunit clustering and hyperexcitability well before the onset of a detectable diseaseD006816-like behavioral phenotype. In addition, activity-dependent re-organization of synaptic protein nanostructure, and functional measures of synaptic plasticity were impaired in presymptomatic diseaseD006816 10090. These data demonstrate that diseaseD012183 in the presymptomatic diseaseD006816 brain are not exclusive to the striatum, and highlight the need to better understand the region-dependent complexities of early synaptopathy in the diseaseD006816 brain.
35649655		- No Title -
34663644	Association|diseaseD000068079|ncbi9900; Association|diseaseD006816|ncbi9900; Association|chemicalC000618323|ncbi9900; Negative_Correlation|chemicalD019788|diseaseD006816	diseaseD012183 and Its Clinical Correlates in People With Early diseaseD006816: A PET Study.BACKGROUND AND OBJECTIVES: diseaseD012183 has been proposed to play a major role in the pathophysiology of diseaseD006816 (diseaseD006816), but in vivo evidence in 9606 is lacking. We performed a PET imaging study to assess diseaseD012183 and its clinical correlates in early diseaseD006816 in vivo. METHODS: In this cross-sectional study, premanifest and early manifest (Shoulson-Fahn stage 1 and 2) diseaseD006816 mutation carriers and age- and sex-matched healthy controls underwent clinical assessment of motor and nonmotor manifestations and time-of-flight PET with chemicalC000618323, a radioligand targeting the ubiquitous presynaptic terminal marker ncbi9900 (ncbi9900). We also performed chemicalD019788 (chemicalD019788)-PET in all participants because regional cerebral chemicalD005947 consumption is thought to largely reflect synaptic activity. Volumes of interest were delineated on the basis of individual 3-dimensional T1 MRI. Standardized uptake value ratio-1 images were calculated for chemicalC000618323 with the centrum semiovale as reference region. chemicalD019788-PET activity was normalized to the pons. All PET data were corrected for partial volume effects. Volume of interest- and voxel-based analyses were performed. Correlations between clinical scores and chemicalC000618323 PET data were calculated. RESULTS: Eighteen diseaseD006816 mutation carriers (age 51.4 +- 11.6 years; 6 female; 7 premanifest, 11 early manifest) and 15 healthy controls (age 52.3 +- 3.5 years; 4 female) were included. In the diseaseD006816 group, significant loss of ncbi9900 binding was found in putamen, caudate, pallidum, cerebellum, parietal, and temporal and frontal cortex, whereas reduced chemicalD019788 uptake was restricted to caudate and putamen. In the premanifest subgroup, chemicalC000618323 and chemicalD019788-PET showed significant reductions in putamen and caudate only. In the total diseaseD006816 group, ncbi9900 loss in the putamen correlated with diseaseD000068079. DISCUSSION: Our data reveal loss of presynaptic terminal integrity in early diseaseD006816, which begins in the striatum in the premanifest phase, spreads extensively to extrastriatal regions in the early manifest phase, and correlates with diseaseD000068079. chemicalC000618323 PET is more sensitive than chemicalD019788-PET for detection of extrastriatal changes in early diseaseD006816. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that chemicalC000618323 PET accurately discriminates individuals diseaseD006816 from normal controls.
37652706		Pearls & Oy-sters: diseaseD004827 is a key feature of pediatric-onset diseaseD006816.Pediatric-onset diseaseD006816 (diseaseD006816) presents differently from adult-onset disease. Children typically exhibit regression in school performance, diseaseD001523 features such as diseaseD001308, and diseaseD000068079. Unlike adult-onset diseaseD006816, in which diseaseD012640 occur at approximately the rate of the general public, at least half of children with diseaseD006816 develop diseaseD004827 and diseaseD012640 can be a presenting feature of diseaseD006816. Here we present the case of a 10-year-old boy with a history of diseaseD007805, motor regression, diseaseD000068079, and diseaseD014202 who presented with a first lifetime diseaseD012640. Given a family history of diseaseD006816 in his father, diseaseD006816 was considered, and a pathogenic allele with 88 repeats was confirmed in the child. As symptoms progressed, history alone could not differentiate diseaseD004409 from diseaseD012640. Continuous video electroencephalography helped to demonstrate diseaseD009207 and guide treatment.
36098670	Negative_Correlation|chemicalC000609690|diseaseD004409; Negative_Correlation|chemicalC000609690|diseaseD002819; Negative_Correlation|chemicalC000609690|diseaseD006816	Evaluation of chemicalC000609690's Potential to Delay Cardiac Repolarization Using Concentration-QTc Analysis.chemicalC000609690 (chemicalC000609690) is indicated in adults for diseaseD002819 associated with diseaseD006816 and diseaseD004409. Escalating chemicalC000609690 doses were administered to healthy volunteers who were ncbi107987479 extensive/intermediate metabolizers (EMs) or poor metabolizers (PMs) to determine pharmacokinetic exposure of parent drug and active metabolites (alpha-dihydrotetrabenazine [alpha-HTBZ] and beta-dihydrotetrabenazine [beta-HTBZ]), and collect corresponding electrocardiograms (ECGs) for evaluation of the cardiodynamic effect using concentration-QTc (C-QTc) modeling. Participants (12 EMs, 24 PMs) received placebo or single doses of chemicalC000609690 (24, 48, and 72 mg) to achieve plasma concentrations exceeding therapeutic range in both cohorts. Pharmacokinetic samples were obtained over 72 hours after dosing and were time matched with 12-lead ECGs extracted from continuous ECG recordings. C-QTc analysis, using linear mixed-effects modeling and model selection procedure, characterized the relationship between plasma concentrations of chemicalC000609690, deuterated alpha-HTBZ and beta-HTBZ, and the change from baseline in QT interval corrected using Fridericia's formula. chemicalC000609690 exhibited linear kinetics, and a C-QTc model with deuterated alpha-HTBZ and beta-HTBZ was selected to best describe the C-QTc relationship in pooled EM and PM data. This model predicted a placebo-corrected Fridericia corrected diseaseD008133 higher than 10 milliseconds can be excluded at concentrations associated with the maximum recommended doses in both populations. Adverse events increased with higher exposure as reflected by the higher event number in the PM cohort receiving 48 and 72 mg doses. No subject discontinued due to cardiac-related adverse events and no clinically relevant ECG findings were reported. Thus, this study found that chemicalC000609690 does not have a clinically relevant effect on diseaseD008133 at maximum recommended doses in either ncbi107987479 EMs or PMs.
35618525		In vitro fertilization with preimplantation genetic testing for diseaseD004194 versus unassisted conception with prenatal diagnosis for diseaseD006816: a cost-effectiveness analysis.OBJECTIVE: To investigate if in vitro fertilization (IVF) with preimplantation genetic testing for diseaseD004194 is cost effective for heterozygous individuals with diseaseD006816 vs. unassisted conception with prenatal diagnosis. DESIGN: Cost-effectiveness analysis in a theoretical cohort of 3,851 couples, where one individual is heterozygous for diseaseD006816. SETTING: N/A. 9606/diseaseD000820: None. INTERVENTION: In vitro fertilization preimplantation genetic testing for couples attempting conception. MAIN OUTCOME MEASURES: Outcomes included cost and quality-adjusted life years (QALYs) for both parents in addition to secondary outcomes of procedure-related loss, spontaneous abortion, termination of pregnancy, and early/normal/late-onset diseaseD006816. A willingness-to-pay threshold was set at $100,000/QALY. RESULTS: In vitro fertilization preimplantation genetic testing is lower in cost and higher in effectiveness compared to unassisted conception with prenatal diagnosis among couples with one heterozygous diseaseD006816 individual, making it the dominant strategy. In vitro fertilization preimplantation genetic testing was associated with 77 more QALYs and a cost savings of $46,394,268. All measured outcomes were lower in the IVF preimplantation genetic testing strategy, including 39 fewer procedure-related losses, 39 fewer spontaneous diseaseD000026, and 462 fewer terminations of pregnancy. Most notably, in our theoretical cohort of couples, IVF preimplantation genetic testing resulted in 1,079 fewer diseaseD006816-affected offspring. Our results were robust over a wide range of assumptions. CONCLUSION: In vitro fertilization preimplantation genetic testing is a cost-effective conception strategy compared to unassisted conception with prenatal diagnosis when one individual is heterozygous for diseaseD006816. Not only can morbidity and mortality incurred by diseaseD006816 be mitigated for the offspring with the use of IVF preimplantation genetic testing, but this study demonstrates the cost-effectiveness of using IVF preimplantation genetic testing for those with diseaseD006816.
32499373	Association|diseaseD006816|ncbi15194	FACS-array-based cell purification yields a specific transcriptome of striatal medium spiny neurons in a 10090 diseaseD006816 model.diseaseD006816 (diseaseD006816) is a diseaseD019636 caused by expanded CAG repeats in the ncbi15194 gene. Results from previous studies have suggested that transcriptional dysregulation is one of the key mechanisms underlying striatal diseaseD009410 in diseaseD006816. However, some of the critical genes involved in diseaseD006816 etiology or pathology could be masked in a common expression profiling assay because of contamination with non-MSN cells. To gain insight into the MSN-specific gene expression changes in presymptomatic R6A628 10090, a common diseaseD006816 10090 model, here we used a transgenic fluorescent protein marker of MSNs for purification via FACS before profiling gene expression with gene microarrays and compared the results of this "FACS-array" with those obtained with homogenized striatal samples (STR-array). We identified hundreds of differentially expressed genes (DEGs) and enhanced detection of MSN-specific DEGs by comparing the results of the FACS-array with those of the STR-array. The gene sets obtained included genes ubiquitously expressed in both MSNs and non-MSN cells of the brain and associated with transcriptional regulation and DNA damage responses. We proposed that the comparative gene expression approach using the FACS-array may be useful for uncovering the gene cascades affected in MSNs during diseaseD006816 pathogenesis.
34239038	Association|diseaseD006816|ncbi3064; Association|chemicalC097188|ncbi3064; Positive_Correlation|chemicalC097188|diseaseD006816	Cryo-electron tomography provides topological insights into mutant ncbi3064 exon 1 and chemicalC097188 aggregates.diseaseD006816 (diseaseD006816) is a neurodegenerative diseaseD030342 caused by an expanded chemicalC097188 (chemicalC097188) tract in the mutant ncbi3064 (mHTT) protein. The formation and topology of filamentous mHTT inclusions in the brain (hallmarks of diseaseD006816 implicated in diseaseD020258) remain elusive. Using cryo-electron tomography and subtomogram averaging, here we show that mHTT exon 1 and chemicalC097188-only aggregates in vitro are structurally heterogenous and filamentous, similar to prior observations with other methods. Yet, we find filaments in both types of aggregates under ~2 nm in width, thinner than previously reported, and regions forming large sheets. In addition, our data show a prevalent subpopulation of filaments exhibiting a lumpy slab morphology in both aggregates, supportive of the chemicalC097188 core model. This provides a basis for future cryoET studies of various aggregated mHTT and chemicalC097188 constructs to improve their structure-based modeling as well as their identification in cells without fusion tags.
35986957		Emotion expression through spoken language in diseaseD006816.9606 with diseaseD006816 suffer from disturbances in the perception of emotions; they do not correctly read the body, vocal and facial expressions of others. With regard to the expression of emotions, it has been shown that they are impaired in expressing emotions through face but up until now, little research has been conducted about their ability to express emotions through spoken language. To better understand emotion production in both voice and language in diseaseD006816 (diseaseD006816), we tested 115 individuals: 68 9606 (diseaseD006816), 22 9606 carrying the mutant diseaseD006816 gene without any motor symptoms (pre-manifest diseaseD006816), and 25 controls in a single-centre prospective observational follow-up study. 9606 were recorded in interviews in which they were asked to recall sad, angry, happy, and neutral stories. Emotion expression through voice and language was investigated by comparing the identifiability of emotions expressed by controls, preHD and diseaseD006816 9606 in these interviews. To assess separately vocal and linguistic expression of emotions in a blind design, we used machine learning models instead of a 9606 jury performing a forced-choice recognition test. Results from this study showed that 9606 with diseaseD006816 had difficulty expressing emotions through both voice and language compared to preHD 9606 and controls, who behaved similarly and above chance. In addition, we did not find any differences in expression of emotions between preHD and healthy controls. We further validated our newly proposed methodology with a 9606 jury on the speech produced by the controls. These results are consistent with the hypothesis that diseaseD001289 in diseaseD006816 are caused by impaired sensori-motor representations of emotions, in line with embodied cognition theories. This study also shows how machine learning models can be leveraged to assess emotion expression in a blind and reproducible way.
38092268	Association|ncbi12368|ncbi15194; Association|diseaseD006816|ncbi15194	Reducing ncbi15194 by immunotherapy delays disease progression in a 10090 model of diseaseD006816.In diseaseD006816 (diseaseD006816), the mutant ncbi15194 (mtHTT) protein is the principal cause of pathological changes that initiate primarily along the cortico-striatal axis. mtHTT is ubiquitously expressed and there is, accordingly, growing recognition that diseaseD006816 is a diseaseD009422 with functional interplay between the brain and the periphery. We have developed a monoclonal antibody, C6-17, targeting an exposed region of ncbi15194 near the aa586 ncbi12368 cleavage site. As recently published, mAB C6-17 can block cell-to-cell propagation of mtHTT in vitro. In order to reduce the burden of the mutant protein in vivo, we queried whether extracellular mtHTT could be therapeutically targeted in 2244 diseaseD006816 10090. In a series of proof of concept experiments, we found that systemic mAB C6-17 treatment resulted in the distribution of the mAB C6-17 to peripheral and CNS tissues and led to the reduction of ncbi15194 protein levels. Compared to CTRL chemicalD000911 or vehicle treated 10090, the mAB C6-17 treated 2244 animals showed improved body weight and motor behaviors, a delayed progression in diseaseD009461 and reduced striatal EM48 immunoreactivity. These results provide the first proof of concept for the feasibility and therapeutic efficacy of an antibody-based anti-ncbi15194 passive immunization approach and suggest this modality as a potential new diseaseD006816 treatment strategy.
32743645	Positive_Correlation|chemicalD017378|diseaseC537500; Negative_Correlation|chemicalC000179|chemicalD017378; Association|chemicalD017378|diseaseD006816	Longitudinal Magnetic Resonance Spectroscopy and Diffusion Tensor Imaging in 9940 (9940) With chemicalD017378 Lesions of the Striatum: Time-Dependent Recovery of chemicalC000179 and Fractional Anisotropy.We created an excitotoxic diseaseC537500 model of diseaseD006816 (diseaseD006816) in 9940, using the N-methyl-d-aspartate receptor agonist, chemicalD017378 (chemicalD017378). Sixteen 9940 received a bolus infusion of chemicalD017378 (75 microL, 180 mM) or saline, first into the left and then (4 weeks later) into the right striatum. Magnetic resonance spectroscopy (MRS) and diffusion tensor imaging (DTI) of the striata were performed. Metabolite concentrations and fractional anisotropy (FA) were measured at baseline, acutely (1 week after each surgery) and chronically (5 weeks or greater after the surgeries). There was a significant decrease in the neuronal marker chemicalC000179 (chemicalC000179) and in FA in acutely lesioned striata of the chemicalD017378-lesioned 9940, followed by a recovery of chemicalC000179 and FA in the chronically lesioned striata. chemicalC000179 level changes indicate acute death and/or impairment of neurons immediately after surgery, with recovery of reversibly impaired neurons over time. The change in FA values of the chemicalD017378-lesioned striata is consistent with acute structural disruption, followed by re-organization and glial cell infiltration with time. Our study demonstrates that MRS and DTI changes in chemicalD017378-9940 are consistent with diseaseD006816-like pathology shown in other model species and that the MR investigations can be performed in 9940 using a clinically relevant 9606 3T MRI scanner.
33974252		[Genetic testing and prenatal diagnosis of two pedigrees affected with diseaseD006816].OBJECTIVE: To explore the genetic basis for two Chinese pedigrees affected with diseaseD006816 and provide prenatal diagnosis for them. METHODS: Peripheral venous blood samples were collected from the probands. PCR and capillary gel electrophoresis were used to determine the number of CAG repeats in their ncbi3064 gene. Pre-symptomatic testing was offered to their children and relatives, and prenatal diagnosis was provided to three pregnant 9606 from the two pedigrees. RESULTS: The two probands, in addition with three asymptomatic members, were found to have a (CAG)n repeat number greater than 40. Upon prenatal diagnosis, the numbers of CAG repeats in two fetuses from pedigree 1 were determined as (16, 19) and (18, 19), both were within the normal range. A fetus from pedigree 2 was found to have a CAG repeat number of (15, 41), which exceeded the normal range. CONCLUSION: Genetic testing can facilitate the diagnosis of diseaseD006816 and avoid further birth of affected children.
37591545		In Vivo Cerebral Imaging of Mutant Huntingtin Aggregates Using 11C-CHDI-180R PET in a Nonhuman Primate Model of diseaseD006816.diseaseD006816 (diseaseD006816) is a diseaseD019636 caused by an expanded polyglutamine (CAG) trinucleotide expansion in the ncbi700306 (ncbi700306) gene that encodes the mutant ncbi700306 protein (mHTT). Visualization and quantification of cerebral mHTT will provide a proxy for target engagement and a means to evaluate therapeutic interventions aimed at lowering mHTT in the brain. Here, we validated the novel radioligand chemicalC000615233-labeled 6-(5-((5-methoxypyridin-2-yl)methoxy)benzo[d]oxazol-2-yl)-2-methylpyridazin-3(2H)-one (11C-CHDI-180R) using PET imaging to quantify cerebral mHTT aggregates in a macaque model of diseaseD006816. Methods: Rhesus macaques received MRI-guided intrastriatal delivery of a mixture of AAV2 and AAV2.retro viral vectors expressing an ncbi700306 fragment bearing 85 CAG repeats (85Q, n = 5), a control ncbi700306 fragment bearing 10 CAG repeats (10Q, n = 4), or vector diluent only (phosphate-buffered saline, n = 5). Thirty months after surgery, 90-min dynamic PET/CT imaging was used to investigate 11C-CHDI-180R brain kinetics, along with serial blood sampling to measure input function and stability of the radioligand. The total volume of distribution was calculated using a 2-tissue-compartment model as well as Logan graphical analysis for regional quantification. Immunostaining for mHTT was performed to corroborate the in vivo findings. Results: 11C-CHDI-180R displayed good metabolic stability (51.4% +- 4.0% parent in plasma at 60 min after injection). Regional time-activity curves displayed rapid uptake and reversible binding, which were described by a 2-tissue-compartment model. Logan graphical analysis was associated with the 2-tissue-compartment model (r 2 = 0.96, P < 0.0001) and used to generate parametric volume of distribution maps. Compared with controls, animals administered the 85Q fragment exhibited significantly increased 11C-CHDI-180R binding in several cortical and subcortical brain regions (group effect, P < 0.0001). No difference in 11C-CHDI-180R binding was observed between buffer and 10Q animals. The presence of mHTT aggregates in the 85Q animals was confirmed histologically. Conclusion: We validated 11C-CHDI-180R as a radioligand to visualize and quantify mHTT aggregated species in a diseaseD006816 macaque model. These findings corroborate our previous work in rodent diseaseD006816 models and show that 11C-CHDI-180R is a promising tool to assess the mHTT aggregate load and the efficacy of therapeutic strategies.
34120903		Research on Emotion Recognition and diseaseD003704: Foundations and Prospects.BACKGROUND: The study of emotion recognition could be crucial for detecting alterations in certain cognitive areas or as an early sign of diseaseD009461. OBJECTIVE: The main objective of the study is to characterize research development on emotion recognition, identifying the intellectual structure that supports this area of knowledge, and the main lines of research attracting investigators' interest. METHODS: We identified publications on emotion recognition and diseaseD003704 included in the Web of Science Core Collection, analyzing the scientific output and main disciplines involved in generating knowledge in the area. A co-citation analysis and an analysis of the bibliographic coupling between the retrieved documents elucidated the thematic orientations of the research and the reference works that constitute the foundation for development in the field. RESULTS: A total of 345 documents, with 24,282 bibliographic references between them, were included. This is an emerging research area, attracting the interest of investigators in Neurosciences, Psychology, Clinical Neurology, and Psychiatry, among other disciplines. Four prominent topic areas were identified, linked to diseaseD057180, diseaseD000067877, diseaseD000544, and diseaseD010300. Many recent papers focus on the detection of mild diseaseD003072. CONCLUSION: diseaseD020238 may be a key sign facilitating the diagnosis and early treatment of different diseaseD019636 as well as for triggering the necessary provision of social and family support, explaining the growing research interest in this area.
36513779		Cognition-oriented treatments and physical exercise on cognitive function in diseaseD006816: a systematic review.diseaseD003072 is prevalent in diseaseD006816 (diseaseD006816), with no treatments currently available. While cognition-oriented treatments and physical exercise have shown efficacy in improving cognition in other populations, they have not been systematically reviewed in diseaseD006816. This systematic review aims to examine the effects of cognitive and exercise interventions on cognition in diseaseD006816, along with effects on psychosocial function, functional independence, and neuroimaging outcomes. Seventeen studies (three cognitive, seven exercise, seven combining cognitive and physical exercise) were included. While there was generally low certainty of evidence, interventions that included cognitive training appeared to have larger effect sizes on cognition, while physical exercise (alone or combined with cognitive rehabilitation or stimulation) showed negligible effect sizes. On the other hand, combined interventions had larger effects on psychosocial function. Finally, effects on functional independence appeared negligible following exercise and combined interventions, and effects on neuroimaging outcomes were inconclusive. Larger studies should seek to confirm the benefits of cognitive and physical interventions, and further explore changes in functional independence and neural outcomes.
37751638		The shape of things to come. Mapping spatiotemporal progression of striatal morphology in diseaseD006816: The IMAGE-diseaseD006816 study.Mapping the spatiotemporal progression of neuroanatomical change in diseaseD006816 (diseaseD006816) is fundamental to the development of bio-measures for prognostication. Statistical shape analysis to measure the striatum has been performed in diseaseD006816, however there have been a limited number of longitudinal studies. To address these limitations, we utilised the Spherical Harmonic Point Distribution Method (SPHARM-PDM) to generate point distribution models of the striatum in individuals, and used linear mixed models to test for localised shape change over time in pre-manifest diseaseD006816 (pre-diseaseD006816), symp-diseaseD006816 (symp-diseaseD006816) and control individuals. Longitudinal MRI scans from the IMAGE-diseaseD006816 study were used (baseline, 18 and 30 months). We found significant differences in the shape of the striatum between groups. Significant group-by-time interaction was observed for the putamen bilaterally, but not for caudate. A differential rate of shape change between groups over time was observed, with more significant deflation in the symp-diseaseD006816 group in comparison with the pre-diseaseD006816 and control groups. CAG repeats were correlated with bilateral striatal shape in pre-diseaseD006816 and symp-diseaseD006816. Robust statistical analysis of the correlates of striatal shape change in diseaseD006816 has confirmed the suitability of striatal morphology as a potential biomarker correlated with CAG-repeat length, and potentially, an endophenotype.
36706436		Factors Associated with the Place of diseaseD003643 in diseaseD006816: Analysis of Enroll-diseaseD006816.Background: Most people prefer to die at home. Hospice is the standard in end-of-life care for people with diseaseD006816 (diseaseD006816), a diseaseD019636 that affects people in middle adulthood. Yet, we have little knowledge regarding the place of diseaseD003643 for people with diseaseD006816. Therefore, the current state of knowledge limits diseaseD006816 clinicians' ability to conduct high-quality goals of care conversations. Objectives: We sought to determine the factors associated with the place of diseaseD003643 in people with diseaseD006816. Design: We obtained cross-sectional data from Enroll-diseaseD006816 and included participants with a positive diseaseD006816 mutation of 36 or more CAG repeats. Results: Out of 16,120 participants in the Enroll-diseaseD006816 study, 536 were reported as deceased. The mean age at diseaseD003643 was 60. The leading place of diseaseD003643 was home (29%), followed by the hospital (23%). The adjusted odds ratio (aOR) of dying at a skilled nursing facility was significantly lower for those partnered (aOR: 0.48, confidence interval [95% CI]: 0.26-0.86). The aOR for dying on hospice compared to home was increased in a person with some college and above (aOR: 2.40, 95% CI: 1.21-4.75). Conclusions: Our data further suggest that models that predict the place of diseaseD003643 for serious illnesses do not appear to generalize to diseaseD006816. The distribution in the places of diseaseD003643 within diseaseD006816 was not uniform. Our findings may assist diseaseD006816 clinicians in communication during goals of care conversations.
32796930	Negative_Correlation|chemicalD009841|diseaseD006816; Association|diseaseD006816|ncbi3064	diseaseD006816: new insights into molecular pathogenesis and therapeutic opportunities.diseaseD006816 (diseaseD006816) is a diseaseD019636 caused by CAG repeat expansion in the ncbi3064 gene (HTT) and involves a complex web of pathogenic mechanisms. Mutant HTT (mHTT) disrupts transcription, interferes with immune and mitochondrial function, and is aberrantly modified post-translationally. Evidence suggests that the mHTT RNA is toxic, and at the DNA level, somatic CAG repeat expansion in vulnerable cells influences the disease course. Genome-wide association studies have identified DNA repair pathways as modifiers of somatic instability and disease course in diseaseD006816 and other repeat expansion diseases. In animal models of diseaseD006816, nucleocytoplasmic transport is disrupted and its restoration is neuroprotective. Novel cerebrospinal fluid (CSF) and plasma biomarkers are among the earliest detectable changes in individuals with premanifest diseaseD006816 and have the sensitivity to detect therapeutic benefit. Therapeutically, the first 9606 trial of an HTT-lowering antisense chemicalD009841 successfully, and safely, reduced the CSF concentration of mHTT in individuals with diseaseD006816. A larger trial, powered to detect clinical efficacy, is underway, along with trials of other HTT-lowering approaches. In this Review, we discuss new insights into the molecular pathogenesis of diseaseD006816 and future therapeutic strategies, including the modulation of DNA repair and targeting the DNA mutation itself.
34330748	Negative_Correlation|chemicalD018698|ncbi108068; Positive_Correlation|chemicalC118218|ncbi108068; Negative_Correlation|chemicalC118218|ncbi26413; Association|diseaseD006816|ncbi53623; Positive_Correlation|chemicalC118218|ncbi108069; Positive_Correlation|chemicalD018698|diseaseD006816; Negative_Correlation|chemicalD018698|ncbi108069; Positive_Correlation|diseaseD000068079|ncbi108068; Association|diseaseD006816|ncbi14800; Association|diseaseD006816|ncbi108068; Negative_Correlation|chemicalC118218|ncbi11651; Positive_Correlation|diseaseD000068079|ncbi108069; Negative_Correlation|chemicalC118218|ncbi15194; Association|diseaseD006816|ncbi108069; Negative_Correlation|chemicalC118218|ncbi26417; Negative_Correlation|chemicalC118218|diseaseD000068079	Metabotropic ncbi14800 Activation Improves Motor Performance and Reduces Pathology in Heterozygous zQ175 diseaseD006816 10090.diseaseD006816 (diseaseD006816) is an diseaseD019636 that leads to progressive diseaseD000068079 with no available disease-modifying treatment. Current evidence indicates that exacerbated postsynaptic chemicalD018698 signaling in the striatum plays a key role in the pathophysiology of diseaseD006816. However, it remains unclear whether reducing chemicalD018698 release can be an effective approach to slow the progression of diseaseD006816. Here, we show that the activation of ncbi108068 (ncbi108068), which inhibit presynaptic chemicalD018698 release, improves diseaseD006816 symptoms and pathology in heterozygous zQ175 knockin 10090. Treatment of both male and female zQ175 10090 with the potent and selective ncbi108068 agonist chemicalC118218 for either 4 or 8 weeks improves both limb coordination and locomotor function in all 10090. chemicalC118218 also reduces mutant ncbi15194 aggregate formation, neuronal cell death, and microglial activation in the striatum of both male and female zQ175 10090. The reduction in mutant ncbi15194 aggregates correlates with the activation of a ncbi56637-dependent autophagy pathway in male, but not female, zQ175 10090. Furthermore, chemicalC118218 reduces both ncbi11651 and ncbi26417 phosphorylation in male A8KI 10090 but increases both ncbi11651 and ncbi26417 phosphorylation in female A8KI 10090. Taken together, our results indicate that ncbi108068 activation mitigates diseaseD006816 neuropathology in both male and female 10090 but is associated with the differential activation and inactivation of cell signaling pathways in heterozygous male and female zQ175 10090. This further highlights the need to take sex into consideration when developing future diseaseD006816 therapeutics. SIGNIFICANCE STATEMENT: The ncbi108068 agonist chemicalC118218 improves diseaseD000068079 and reduces pathology in male and female zQ175 diseaseD006816 10090. The beneficial outcomes of chemicalC118218 treatment in diseaseD006816 10090 were mediated by divergent cell signaling pathways in both sexes. We provide evidence that ncbi108068 agonists can be repurposed for the treatment of diseaseD006816, and we emphasize the importance of investigating sex as a biological variable in preclinical disease-modifying studies.
33918672	Association|diseaseD006816|ncbi41709; Association|diseaseD006816|ncbi43392; Association|ncbi41709|ncbi43856; Association|diseaseD006816|ncbi43856	Genetic Screen in Adult 7227 Reveals That ncbi43856 Depletion in Glial Cells Mitigates diseaseD006816 Pathology through a ncbi41709-Dependent Pathway.diseaseD006816 (diseaseD006816) is a progressive and fatal diseaseD019636 caused by a CAG repeat expansion in the first exon of the ncbi43392 gene (HTT). In spite of considerable efforts, there is currently no treatment to stop or delay the disease. Although HTT is expressed ubiquitously, most of our knowledge has been obtained on neurons. More recently, the impact of mutant ncbi43392 (mHTT) on other cell types, including glial cells, has received growing interest. It is currently unclear whether new pathological pathways could be identified in these cells compared to neurons. To address this question, we performed an in vivo screen for modifiers of mutant ncbi43392 (HTT-548-128Q) induced pathology in 7227 adult glial cells and identified several putative therapeutic targets. Among them, we discovered that partial ncbi43856/ncbi43856 depletion in these cells was protective, as revealed by strongly increased lifespan and restored locomotor activity. Thus, ncbi43856 promotes the diseaseD006816 pathology in glial cells, in contrast to previous opposite findings in neurons. Further investigations implicated the transcriptional activator ncbi41709 as a critical downstream player in this glial protective pathway. Our data suggest that combinatorial approaches combined to specific tissue targeting may be required to uncover efficient therapies in diseaseD006816.
38394831		CRISPR-Based Gene Editing Techniques in Pediatric diseaseD009461.The emergence of gene editing technologies offers a unique opportunity to develop mutation-specific treatments for pediatric diseaseD009461. Gene editing systems can potentially alter disease trajectory by correcting dysfunctional mutations or therapeutically altering gene expression. Clustered regularly interspaced short palindromic repeats (CRISPR)-based approaches are attractive gene therapy platforms to personalize treatments because of their specificity, ease of design, versatility, and cost. However, many such approaches remain in the early stages of development, with ongoing efforts to optimize editing efficiency, minimize unintended off-target effects, and mitigate pathologic immune responses. Given the rapid evolution of CRISPR-based therapies, it is prudent for the clinically based child neurologist to have a conceptual understanding of what such therapies may entail, including both benefits and risks and how such therapies may be clinically applied. In this review, we describe the fundamentals of CRISPR-based therapies, discuss the opportunities and challenges that have arisen, and highlight preclinical work in several pediatric diseaseD020271.
33658662		hiPSCs for predictive modelling of diseaseD019636: dreaming the possible.9606 induced pluripotent stem cells (hiPSCs) were first generated in 2007, but the full translational potential of this valuable tool has yet to be realized. The potential applications of hiPSCs are especially relevant to neurology, as brain cells from 9606 are rarely available for research. hiPSCs from individuals with diseaseD019636 have facilitated biological and multi-omics studies as well as large-scale screening of chemical libraries. However, researchers are struggling to improve the scalability, reproducibility and quality of this descriptive disease modelling. Addressing these limitations will be the first step towards a new era in hiPSC research - that of predictive disease modelling - involving the correlation and integration of in vitro experimental data with longitudinal clinical data. This approach is a key element of the emerging precision medicine paradigm, in which hiPSCs could become a powerful diagnostic and prognostic tool. Here, we consider the steps necessary to achieve predictive modelling of diseaseD019636 with hiPSCs, using diseaseD006816 as an example.
37379724	Association|diseaseD008113|ncbi203228; Association|diseaseD017096|ncbi5621; Association|diseaseD057180|ncbi203228; Association|diseaseD000690|ncbi203228; Association|diseaseD002524|ncbi10273	Genetic screening for diseaseD006816 phenocopies in Sweden: A tertiary center case series focused on diseaseD030342.OBJECTIVE: To perform a screening for diseaseD006816 (diseaseD006816) phenocopies in a Swedish cohort. METHODS: Seventy-three DNA samples negative for diseaseD006816 were assessed at a tertiary center in Stockholm. The screening included analyses for ncbi203228-diseaseD057180/diseaseD000690 (ncbi203228-diseaseD057180/diseaseD008113), octapeptide repeat insertions (OPRIs) in ncbi5621 associated with diseaseD017096 (diseaseD017096), diseaseC564708 (diseaseC564708), diseaseD020754 (diseaseD020754), diseaseD017827 (diseaseD017827) and diseaseC564616 (diseaseC564616). Targeted genetic analysis was carried out in two cases based on the salient phenotypic features. RESULTS: The screening identified two patients with diseaseC564616, one patient with diseaseD017096 associated with diseaseD008232 but none with nucleotide expansions in ncbi203228 or for diseaseC564708, diseaseD020754 or diseaseD017827. Furthermore, diseaseC536096 (diseaseC536096) and diseaseD002819 (diseaseD002819) was diagnosed in two sporadic cases. WES identified VUS in ncbi10273 in two patients with predominant diseaseD002524. CONCLUSIONS: Our results are in keeping with previous screenings and suggest that other genes yet to be discovered are involved in the etiology of diseaseD006816 phenocopies.
33130907		diseaseD014786 and diseaseD001523 in pre-manifest diseaseD006816.diseaseD006816 (diseaseD006816) is a diseaseD019636 that affects not only the motor but also the cognitive and the neuropsychiatric domain. In particular, diseaseD001523 may emerge already at early pre-manifest stages of the disease. The aim of this research was to explore the relation between visual scanning behavior and complex mental state recognition in individuals with pre-manifest diseaseD006816 (diseaseD006816). Eighteen diseaseD006816 and eighteen age- and gender-matched healthy controls took the revised "Reading the Mind in the Eyes" test while their eye-movements were tracked. In addition to the expected diseaseD001523, diseaseD006816 showed abnormalities concerning all three scanning variables we considered, namely the absolute number of fixations (FC), the average fixation duration (AFD), and the percentage of time spent fixating (FTR). In diseaseD006816, FC and FTR but not AFD predicted mental state recognition over and beyond general disease-related declines in cognition and motor functioning. Notably, diseaseD006816 showed abnormal vertical and horizontal fixation patterns, and these patterns predicted mental state recognition, suggesting the involvement of mechanisms related to the embodied processing of emotional stimuli. Overall, our results suggest that impaired facial mental state recognition in pre-manifest diseaseD006816 is partly due to emotional-motivational factors affecting the visual scanning of facial expressions.
33703929		diseaseD020767, diseaseD009503 and diseaseD018798 in diseaseD006816.Neurologic and nonneurologic manifestations have been shown for diseaseD006816 (diseaseD006816) as a diseaseD019636. However, diseaseD020767 (diseaseD020767), diseaseD018798 and diseaseD009503 have not been reported as its presentations to date. We introduce the first case of a diseaseD006816 9606 with diseaseD020767, diseaseD018798 and diseaseD009503. All transient and chronic risk factors for development of these manifestations were ruled out. According to the experimental evidences reviewed in this article, we suggest that diseaseD006816 itself could promote formation of diseaseD020767, diseaseD018798 and diseaseD009503 through diseaseD006402.
34924521		Delayed Diagnosis of Childhood-Onset diseaseD006816 in an 8-Year-Old Boy With diseaseC537423.
33538666		126910 in diseaseD009461: Ethnopharmacological Evidence, Mechanism of Action and its Progress in Delivery Systems.BACKGROUND: The underlying cause of major diseaseD019636 remains a healthcare mystery. The thoroughly investigated causes include oxidative stress, diseaseD007249, environmental factor, diseaseD028361, and irregular diseaseD066263. 126910 has been used for more than 2500 years as a useful medicinal plant to improve disease defense, prevent aging, rejuvenate the body in a vulnerable situation, and generate a feeling of mental well-being. However, a persuasive paper emphasizing its neuroprotective nature is missing. OBJECTIVE: In the current review, we have delineated the protective role of 126910 against various diseaseD009461 and its progress in delivery systems. METHODS: The database used in the retrieval of data were PubMed, Scopus, Science direct, and SciFinder. The keywords used were W. somnifera, Ashwagandha, neuroprotective activities, etc. The principal source of the data retrieval includes research articles, review papers, and short communications from reputed publishers, including the New England Journal of Medicine, Elsevier, Nature, Springer, and Taylor & Francis. RESULTS: After an extensive literature review, we found that W. somnifera mitigates various diseaseD009461, including diseaseD010300, diseaseD000544, diseaseD006816, diseaseD004409, diseaseD020521, and diseaseD001007. Furthermore, natural compounds in nano sizes range possess better neuroprotective activity. Consequently, polymeric nanomicelles, nanoparticles, and nanofibers of natural products are used in the treatment of diseaseD019636. CONCLUSION: The current review substantially deciphered the protective role of 126910 against various diseaseD009461. However, future studies are further required better to understand the molecular mechanisms behind their neuroprotective nature.
35234162		Rehabilitation outcomes in diseaseD006816 9606 with low body mass index.OBJECTIVES: A catabolic state and a progressive body diseaseD015431 are a well-documented hallmark of diseaseD006816 (diseaseD006816). No study is still available on the effectiveness of intensive in-hospital rehabilitation in diseaseD006816 9606 with low body mass index (BMI). METHODS: Twenty diseaseD006816 9606 with low BMI value were enrolled in this study. Disease severity was assessed before and after rehabilitation by the Barthel Index, the Total Functional Capacity Scale, and the Physical Performance Test. RESULTS: BMI-scores correlated with clinical measures before and after rehabilitation. All 9606 showed an improvement in outcome measures (p<0.001), and an increase in BMI values (p<0.001) after rehabilitation. Effectiveness of rehabilitation correlated with the values of BMI assessed before reheducational programs (p=0.024) and with BMI values observed in each 9606 in the three months before admission to hospital (p=0.002). CONCLUSIONS: Findings of the current study show that the effectiveness of the rehabilitation is positively correlated with the BMI values and confirm the efficacy of in-hospital intensive rehabilitation as a valid strategy finalized to improve neuromotor performances and global functional recovery even in diseaseD006816 9606 with low BMI and at risk of diseaseD044342.
36881978		Comparative transcriptome analysis identified crucial genes and pathways affecting sperm motility in the reproductive tract of drakes with different libido.Libido can affect the semen quality of male, and the sperm motility in semen quality parameters is a reliable index to evaluate the fertility of male. In drakes, the sperm motility is gradually acquired in testis, epididymis, and spermaduct. However, the relationship between libido and sperm motility in drakes has not been reported and the mechanisms of testis, epididymis, and spermaduct regulating the sperm motility of drakes are unclear. Therefore, the purpose of the present study was to compare the semen quality of drakes with libido level 4 (LL4) and libido level 5 (LL5), and tried to identify the mechanisms regulating the sperm motility in drakes by performing RNA-seq in testis, epididymis, and spermaduct. Phenotypically, the sperm motility of drakes (P < 0.01), weight of testis (P < 0.05), and organ index of epididymis (P < 0.05) in the LL5 group were significantly better than those in LL4 group. Moreover, compared with the LL4 group, the ductal square of seminiferous tubule (ST) in testis was significantly bigger in the LL5 group (P < 0.05), and the seminiferous epithelial thickness (P < 0.01) of ST in testis and lumenal diameter (P < 0.05) of ductuli conjugentes/dutus epididymidis in epididymis were significantly longer in the LL5 group. In transcriptional regulation, in addition to KEGG pathways related to metabolism and oxidative phosphorylation, lots of KEGG pathways associated with immunity, proliferation, and signaling were also significantly enriched in testis, epididymis, and spermaduct, respectively. Furthermore, through the integrated analysis of coexpression network and protein-protein interaction network, 3 genes (including COL11A1, COL14A1, and C3AR1) involved in protein digestion and absorption pathway and Staphylococcus aureus infection pathway were identified in testis, 2 genes (including BUB1B and ESPL1) involved in cell cycle pathway were identified in epididymis, and 13 genes (including DNAH1, DNAH3, DNAH7, DNAH10, DNAH12, DNAI1, DNAI2, DNALI1, NTF3, ITGA1, TLR2, RELN, and PAK1) involved in diseaseD006816 pathway and PI3K-Akt signaling pathway were identified in spermaduct. These genes could play crucial roles in the sperm motility of drakes with different libido, and all data the present study obtained will provide new insights into the molecular mechanisms regulating sperm motility of drakes.
33310205		- No Title -
36270767		Reproductive choices and intrafamilial communication in diseaseD020271 with different self-estimated severities.BACKGROUND: Low uptake of presymptomatic testing and medically assisted reproduction in families impacted by diseaseD020271 prompted us to investigate how reproductive options are considered and whether there is a relationship with perceived severity of the disease. We hypothesised that self-estimated severity would influence opinion on reproductive options and that prenatal/preimplantation diagnosis would be a motivation to inform relatives about their risk. METHODS: We invited people impacted by diseaseD020271 to evaluate the severity of their familial disease using analogic visual scales and to answer questionnaires about reproductive choices and intrafamilial communication. We compared answers between diseases and with the perceived severity of each disease. RESULTS: We analysed 562 questionnaires. Participants were impacted by diseaseD006816 (n=307), diseaseD020754 (n=114), diseaseD009223 (n=82) and diseaseD000690/diseaseD057180 (n=59). Self-estimated severity differed between pathologies (p<0.0001). Overall, participants considered prenatal diagnosis (78.0+-34.4 out of 100) and preimplantation diagnosis (75.2+-36.1 out of 100) justified more than termination of pregnancy (68.6+-38.5 out of 100). They were less in favour of gamete donation (48.3+-39.8 out of 100) or pregnancy abstention (43.3+-40.3 out of 100). The greater the perceived severity of the disease, the more reproductive options were considered justified, except for gamete donation. Prenatal/preimplantation diagnosis was a motivation to inform relatives for only 55.3% of participants (p=0.01). CONCLUSION: Self-estimated severity minimally impacts opinions towards reproductive options. Medically assisted reproduction procedures are rarely sought and do not motivate familial communication.
35396899	Association|chemicalD007501|diseaseD006816	Mutation-related magnetization-transfer, not axon density, drives white matter differences in premanifest diseaseD006816: Evidence from in vivo ultra-strong gradient MRI.White matter (WM) alterations have been observed in diseaseD006816 (diseaseD006816) but their role in the disease-pathophysiology remains unknown. We assessed WM changes in premanifest diseaseD006816 by exploiting ultra-strong-gradient magnetic resonance imaging (MRI). This allowed to separately quantify magnetization transfer ratio (MTR) and hindered and restricted diffusion-weighted signal fractions, and assess how they drove WM microstructure differences between 9606 and controls. We used tractometry to investigate region-specific alterations across callosal segments with well-characterized early- and late-myelinating axon populations, while brain-wise differences were explored with tract-based cluster analysis (TBCA). Behavioral measures were included to explore disease-associated brain-function relationships. We detected lower MTR in 9606' callosal rostrum (tractometry: p = .03; TBCA: p = .03), but higher MTR in their splenium (tractometry: p = .02). Importantly, 9606' mutation-size and MTR were positively correlated (all p-values < .01), indicating that MTR alterations may directly result from the mutation. Further, MTR was higher in younger, but lower in older 9606 relative to controls (p = .003), suggesting that MTR increases are detrimental later in the disease. Finally, 9606 showed higher restricted diffusion signal fraction (FR) from the composite hindered and restricted model of diffusion (CHARMED) in the cortico-spinal tract (p = .03), which correlated positively with MTR in the posterior callosum (p = .033), potentially reflecting compensatory mechanisms. In summary, this first comprehensive, ultra-strong gradient MRI study in diseaseD006816 provides novel evidence of mutation-driven MTR alterations at the premanifest disease stage which may reflect neurodevelopmental changes in chemicalD007501, myelin, or a combination of these.
38272260		Euthanasia and assisted suicide in diseaseD020271: a systematic review.OBJECTIVE: To identify the diseaseD020271 for which euthanasia and assisted suicide are most frequently requested in the countries where these medical procedures are legal and the specific characteristics of euthanasia in some of these diseases, and to show the evolution of euthanasia figures. METHODS: We conducted a systematic literature review. RESULTS: diseaseD003704, diseaseD016472, diseaseD009103, and diseaseD010300 are the diseaseD020271 that most frequently motivate requests for euthanasia or assisted suicide. Requests related to diseaseD003704 constitute the largest group, are growing, and raise additional ethical and legal issues due to these 9606' diminished decision-making capacity. In some countries, the ratios of euthanasia requests to all cases of diseaseD009103, diseaseD016472, or diseaseD006816 are higher than for any other disease. CONCLUSIONS: After diseaseD009369, diseaseD020271 are the most frequent reason for requesting euthanasia or assisted suicide.
33795375	Association|chemicalC000709016|diseaseD006816	Microglia Activation in Basal Ganglia Is a Late Event in diseaseD006816 Pathophysiology.OBJECTIVE: To define the role played by microglia in different stages of diseaseD006816 (diseaseD006816), we used the TSPO radioligand chemicalC000709016 and PET to evaluate microglial activation in relation to diseaseD019636 and in relation to the clinical features seen at premanifest and manifest stages of the disease. METHODS: This is a cross-sectional study in which 18 subjects (6 controls, 6 premanifest, and 6 manifest diseaseD006816 gene carriers) underwent a chemicalC000709016 PET scan and an MRI for anatomic localization. Segmentation of regions of interest (ROIs) was performed, and group differences in chemicalC000709016 binding (used to evaluate the extent of microglial activation) were assessed by the standardized uptake value ratio (SUVR). Microglial activation was correlated with ROIs volumes, disease burden, and the scores obtained in the clinical scales. As an exploratory aim, we evaluated the dynamic functions of microglia in vitro, by using induced microglia-like (iMG) cells from peripheral blood monocytes. RESULTS: Individuals with manifest diseaseD006816 present higher chemicalC000709016 SUVR in both globi pallidi and putamina in comparison with controls. No differences were observed when we compared premanifest diseaseD006816 with controls or with manifest diseaseD006816. We also found a significant correlation between increased microglial activation and cumulative disease burden, and with reduced volumes. iMG from controls, premanifest diseaseD006816, and manifest diseaseD006816 9606 showed similar phagocytic capacity. CONCLUSIONS: Altogether, our data demonstrate that microglial activation is involved in diseaseD006816 pathophysiology and is associated with disease progression.
33044180	Association|diseaseD028361|ncbi351; Association|chemicalD005947|diseaseD000544; Association|diseaseD000544|ncbi351	Role of diseaseD028361 in the Pathology of ncbi351.diseaseD028361 has been widely reported in several diseaseD019636, including in the brains of 9606 with diseaseD000544 (diseaseD000544), diseaseD010300, and diseaseD006816. An increasing number of studies have implicated altered chemicalD005947 and energy metabolism in 9606 with diseaseD000544. There is compelling evidence of abnormalities in some of the key mitochondrial enzymes involved in chemicalD005947 metabolism, including the pyruvate dehydrogenase and alpha-ketoglutarate dehydrogenase complexes, which play a great significance role in the pathogenesis of diseaseD000544. Changes in some of the enzyme activities of the mitochondria found in diseaseD000544 have been linked with the pathology of ncbi351 (ncbi351). This review highlights the role of mitochondrial function in the production and clearance of ncbi351 and how the pathology of ncbi351 leads to a decrease in energy metabolism by affecting mitochondrial function.
33299145		Informing about genetic risk in families with diseaseD006816: comparison of attitudes across two decades.The low uptake of presymptomatic testing in diseaseD006816 prompted us to question family members on how they handle the transmission of information regarding genetic risk. We hypothesised that in 2019, parents would inform their at-risk children about their genetic risk more and at a younger age than in 2000, given the availability of prenatal diagnosis, French legislation changes since 2011, and recent therapeutic advances. We made a questionnaire available about the transmission of genetic information within families with diseaseD006816 in 2000 and 2019. We obtained 443 questionnaires (295 in 2019 and 148 in 2000). Participants were mainly at-risk for diseaseD006816 (n = 113), affected (n = 85), and spouses (n = 154). In 2019, participants had a higher mean education level (p < 0.01) and a mean age of 44.1 +- 15.1 years (vs 48.1 +- 11.4 years in 2000, p < 0.01). They had been informed about the risk of being a carrier at around 30 years of age (29.0 +- 14.2 in 2019 vs 32.2 +- 13.8 in 2000, p = 0.09). However, they would inform at an earlier age (<=18 years, 67% vs 59%, p = 0.16). Information on transmission risk had been given primarily by parents (45% vs 30%, p = 0.06). In addition, genetic testing for relatives unaware of their status was recommended more frequently in 2019 (46% vs 32%, p < 0.001). Respondents in 2019 recommended genetic testing more often but overall attitudes towards information and testing have not changed significantly over the 19-year time period since the questionnaire was first delivered even despite recent clinical trials potential disease modifying therapies.
32265233		Abnormal development of cerebellar-striatal circuitry in diseaseD006816.OBJECTIVE: To test the hypothesis that the trajectory of functional connections over time of the striatum and the cerebellum differs between presymptomatic 9606 with the diseaseD006816 (diseaseD006816) gene expansion (GE) and 9606 with a family history of diseaseD006816 but without the GE (GNE), we evaluated functional MRI data from the Kids-diseaseD006816 study. METHODS: We utilized resting-state, functional MRI data from participants in the Kids-diseaseD006816 study between 6 and 18 years old. Participants were divided into GE (CAG 36-59) and GNE (CAG <36) groups. Seed-to-seed correlations were calculated among 4 regions that provide input signals to the anterior cerebellum: (1) dorsocaudal putamen, (2) globus pallidus externa, (3) subthalamic nucleus, and (4) pontine nuclei; and 2 regions that represented output from the cerebellum: the dentate nucleus to the (1) ventrolateral thalamus and (2) dorsocaudal putamen. Linear mixed effects regression models evaluated differences in developmental trajectories of these connections over time between groups. RESULTS: Four of the six striatal-cerebellum correlations showed significantly different trajectories between groups. All showed a pattern where in the early age ranges (6-12 years) there was hyperconnectivity in the GE compared to the GNE, with those trajectories showing linear decline in the latter half of the age range. CONCLUSION: These results parallel previous findings showing diseaseD006984 in children with GE as early as age 6. These findings support the notion of developmentally higher connectivity between the striatum and cerebellum early in the life of the child with diseaseD006816 GE, possibly setting the stage for cerebellar compensatory mechanisms.
32302555		Stem Cell-Derived 9606 Striatal Progenitors Innervate Striatal Targets and Alleviate Sensorimotor diseaseD009461 in a 10116 Model of diseaseD006816.diseaseD006816 (diseaseD006816) is an inherited late-onset diseaseD009461 characterized by progressive diseaseD009410 and disruption of cortical and basal ganglia circuits. Cell replacement using 9606 embryonic stem cells may offer the opportunity to repair the damaged circuits and significantly ameliorate disease conditions. Here, we showed that in-vitro-differentiated 9606 striatal progenitors undergo maturation and integrate into host circuits upon intra-striatal transplantation in a 10116 model of diseaseD006816. By combining graft-specific immunohistochemistry, 11292-mediated synaptic tracing, and ex vivo electrophysiology, we showed that grafts can extend projections to the appropriate target structures, including the globus pallidus, the subthalamic nucleus, and the substantia nigra, and receive synaptic contact from both host and graft cells with 6.6 +- 1.6 inputs cell per transplanted neuron. We have also shown that transplants elicited a significant improvement in sensory-motor tasks up to 2 months post-transplant further supporting the therapeutic potential of this approach.
37855949		diseaseD019572 in diseaseD019636.Ophthalmic biomarkers have long played a critical role in diagnosing and managing diseaseD005128. Oculomics has emerged as a field that utilizes ocular imaging biomarkers to provide insights into diseaseD034721. Advances in diagnostic and imaging technologies including electroretinography, optical coherence tomography (OCT), confocal scanning laser ophthalmoscopy, fluorescence lifetime imaging ophthalmoscopy, and OCT angiography have revolutionized the ability to understand diseaseD034721 and even detect them earlier than clinical manifestations for earlier intervention. With the advent of increasingly large ophthalmic imaging datasets, machine learning models can be integrated into these ocular imaging biomarkers to provide further insights and prognostic predictions of diseaseD019636. In this manuscript, we review the use of ophthalmic imaging to provide insights into diseaseD019636 including diseaseD000544, diseaseD010300, diseaseD000690, and diseaseD006816. We discuss recent advances in ophthalmic technology including eye-tracking technology and integration of artificial intelligence techniques to further provide insights into these diseaseD019636. Ultimately, oculomics opens the opportunity to detect and monitor diseaseD034721 at a higher acuity. Thus, earlier detection of diseaseD034721 may allow for timely intervention for improving the quality of life in patients with diseaseD019636.
37699467	Association|chemicalD012834|ncbi3630	Characterization of structural changes occurring in ncbi3630 at different time intervals at room temperature by surface-enhanced Raman spectroscopy.BACKGROUND: ncbi3630 storage above the temperature recommended by food and drug administration (FDA) causes decrease in its functional efficacy due to degradation and aggregation of its protein based active pharmaceutical ingredient (API) that results poor glycemic control in diseaseD003920 patients. The aggregation of protein causes serious diseaseD019636 such as diseaseD003924, diseaseD006816, diseaseD010300, and diseaseD000544. Surface-enhanced Raman spectroscopy (SERS) has been employed for the denaturation study of many proteins at the temperature above the recommendations of food and drug administration (FDA) (above 30  C) which indicates potential of technique for such studies. OBJECTIVE: SERS along with multivariate discriminating analysis techniques-based analysis of degradation of liquid pharmaceutical ncbi3630 protein after regular intervals of time at room temperature to analyze the structural changes in this protein during the storage of ncbi3630 pharmaceutical at room temperature. METHODS: chemicalD012834 nanoparticles (Ag-NPs) prepared by chemical reduction method are used as SERS active substrate for the surface enhancement of the ncbi3630 spectral signal. SERS spectral measurements of ncbi3630 were collected from eight different samples of ncbi3630 in the time range of 7pm to 7am first at fridge temperature (5  C), second after half hour and next six with the time difference of 2 hours each time at room temperature. The acquired SERS spectral data was preprocessed and analyzed. SERS structural transformations detection and discrimination potential in ncbi3630 was further confirmed by applying multivariate discriminating analysis techniques including principal component analysis (PCA) and Partial least square regression analysis (PLSR). RESULTS: SERS significantly detects the structural changes produced in ncbi3630 even after 2h of ncbi3630 placement at room temperature. PCA successfully differentiates the ncbi3630 spectral data obtained after regular intervals of time according to PC-1 (77%) explained variance. Application of PLSR model provides quantitative confirmation of SERS efficiency, by providing ncbi3630 data regression coefficients plot, efficient prediction of time with calibration data set having 0.77 mean square absolute error of calibration (RMSAEC), validation data set with 0.80 mean square absolute error of prediction (RMSAEP) and 0.98 coefficient of determination (R2) for both calibration and validation data set. CONCLUSION: SERS is proved as a highly sensitive and discriminating technique to detect and discriminate ncbi3630 structural changes after regular intervals of time at room temperature.
34162958	Association|chemicalC000179|chemicalC027172	Multiparametric characterization of white matter alterations in early stage diseaseD006816.diseaseD006816 (diseaseD006816) is a monogenic, fully penetrant diseaseD019636. Widespread diseaseD056784 affects the brain of 9606 with diseaseD006816 at very early stages of the disease. Fixel-based analysis (FBA) is a novel method to investigate the contribution of individual crossing fibers to the diseaseD056784 and to detect possible alterations in both fiber density and fiber-bundle morphology. Diffusion-weighted magnetic resonance spectroscopy (DW-MRS), on the other hand, quantifies the motion of brain metabolites in vivo, thus enabling the investigation of microstructural alteration of specific cell populations. The aim of this study was to identify novel specific microstructural imaging markers of diseaseD056784 in diseaseD006816, by combining FBA and DW-MRS. Twenty 9606 at an early stage of diseaseD006816 and 20 healthy controls were recruited in a monocentric study. Using diffusion imaging we observed alterations to the brain microstructure and their morphology in 9606 with diseaseD006816. Furthermore, FBA revealed specific fiber populations that were affected by the disease. Moreover, the mean diffusivity of the intra-axonal metabolite chemicalC000179, co-measured with chemicalC027172 (tNAA), was significantly reduced in the corpus callosum of 9606 compared to controls. FBA and DW-MRS of tNAA provided more specific information about the biological mechanisms underlying diseaseD006816 and showed promise for early investigation of diseaseD056784 in diseaseD006816.
32479211		Umbilical cord-derived mesenchymal stem cells in diseaseD019636: from literature to clinical practice.Mesenchymal stem cells (MSCs) have provided a promising tool for cell therapy. Umbilical cord (UC) is one of the best sources of MSCs since its collection is noninvasive, and effortless, and the cells from this source are more capable and prolific. It has been proven that the differentiation, migration and protective properties of UC-MSCs are superior compared with other kinds of stem cells. Moreover, incurable diseaseD019636, such as diseaseD000544, diseaseD009103, diseaseD010300 and diseaseD006816, encourage scientists to apply UC-MSCs transplantation in order to find a definite treatment. This review will focus on the preclinical and clinical use of mesenchymal stem cells derived from 9606 umbilical cord in the treatment of diseaseD019636.
32427942	Positive_Correlation|chemicalD007980|diseaseD006948; Positive_Correlation|chemicalD007980|diseaseD004409; Positive_Correlation|chemicalC015392|diseaseD006948; Negative_Correlation|chemicalD007980|diseaseD010300	Hyperpolarization of the subthalamic nucleus alleviates diseaseD006948.Modulation of subthalamic nucleus (STN) firing patterns with injections of depolarizing currents into the STN is an important advance for the treatment of diseaseD004401, especially diseaseD010300 (diseaseD010300). diseaseD002819, ballism and diseaseD004421 are prototypical examples of diseaseD006948. In our previous study, normal 10116 without diseaseC537500 were rendered diseaseD004401 with hyperpolarizing currents injected into the STN. Therefore, modulation of the firing pattern by injection of a hyperpolarizing current into the STN could be an effective treatment for diseaseD006948. We investigated the effect of injecting a hyperpolarizing current into the STNs of two different types of diseaseD006948 animal models and a 9606 with an otherwise uncontrollable diseaseD006948. The two animal models included chemicalD007980-induced diseaseD006948 in diseaseD010300 10116 (chemicalD007980-induced diseaseD004409 model) and diseaseD006948 induced by an intrastriatal injection of chemicalC015392 (diseaseD006816 model), covering diseaseD019636-related as well as neurotoxin-induced derangement in the cortico-subcortical re-entrant loops. Delivering hyperpolarizing currents into the STN readily alleviated the diseaseD006948 behaviors in the two animal models and in the clinical case, with an evident increase in subthalamic burst discharges in electrophysiological recordings. Application of a hyperpolarizing current into the STN via a Deep brain stimulation (DBS) electrode could be an effective general therapy for a wide spectrum of diseaseD006948.
35812247	Association|diseaseD009369|ncbi89795; Association|ncbi89795|ncbi925; Association|diseaseD015179|ncbi89795; Association|diseaseD006816|ncbi89795; Association|diseaseD000544|ncbi89795; Association|ncbi89795|ncbi920; Association|diseaseD000690|ncbi89795	ncbi89795 Is a Novel Prognostic Biomarker Affecting the Immune Status of the diseaseD009369 Microenvironment in diseaseD015179.diseaseD015179 (diseaseD015179) is one of the most common diseaseD009369 in the world. diseaseD009369 microenvironment (TME) plays a crucial role in the development of diseaseD015179. With the deep understanding of TME function, growing studies have demonstrated that alteration in diseaseD009369-infiltrating immune cells (TICs) and gene expressions are associated with clinical outcomes of various diseaseD009369. In this study, we aimed to recognize critical prognostic genes involved in immune states in TME of diseaseD015179. Hence, the proportion of TICs and the number of immune and stromal components in diseaseD015179 samples from TCGA datasets were calculated by the use of CIBERSORT and ESTIMATE calculation methods. Different assays were applied to collect differential expression genes (DEGs) shared by the ImmuneScore and StromalScore. DEGs were further analyzed by the use of univariate Cox regression. Our attention focused on ncbi89795 (ncbi89795) which was highly expressed in diseaseD015179 specimens and associated with an advanced clinical stage and poor prognosis of diseaseD015179 9606. KEGG assays revealed that ncbi89795 may be involved in diseaseD000544, diseaseD000690, diseaseD006816, FoxO signaling pathway, and human papillomavirus infection. Correlation assays showed that macrophage M0 and B cells memory, NK cells activated, dendritic cells resting, T cells ncbi920 memory activated, and T cells ncbi925 were correlated with ncbi89795 expression, indicating that ncbi89795 may represent the immune status of TME. Finally, RT-PCR confirmed that ncbi89795 expression was distinctly increased in diseaseD015179 cells, and its knockdown suppressed the proliferation of diseaseD015179 cells. Overall, ncbi89795 could be used as a novel predictor for TME of diseaseD015179 and might be a novel prognostic biomarker. In the future, drugs targeting ncbi89795 might be developed as a potential immunotherapy for diseaseD015179 9606.
37040787		[Gene Therapy for diseaseD006816].Englisch: Being one of the most common diseaseD019636, diseaseD006816 has been a model disease - also for gene therapy. Among the various options, the development of antisense chemicalD009841 is the most advanced. Further options at the RNA level include micro-RNAs and modulators of RNA processing (splicing), at the DNA level zinc finger proteins. Several products are in clinical trials. These differ in their mode of application and in the extent of systemic availability. Another important difference between therapeutic strategies could be whether all forms of the ncbi3064 protein are targeted in the same extent, or whether a therapy preferentially targets particular toxic forms such as the exon1 protein. The results of the recently terminated diseaseD004829 trial were somewhat sobering, most likely due to the side effect-related diseaseD006849. Therefore they represent just one step towards the development of an effective gene therapy against diseaseD006816.
33202151	Association|diseaseD006816|ncbi68943; Association|diseaseD010300|ncbi57320; Association|diseaseD000544|ncbi68943; Association|diseaseD010300|ncbi68943; Association|diseaseD006816|ncbi57320; Association|diseaseD000544|ncbi57320	Electroacupuncture Improves Motor Symptoms of diseaseD010300 and Promotes Neuronal Autophagy Activity in 10090 Brain.diseaseC536522 are a hallmark of diseaseD019636, such as diseaseD010300 (diseaseD010300). Enhancing autophagy to remove impaired mitochondria and toxic protein aggregation is an essential component of diseaseD010300 treatment. In particular, activation of autophagy confers neuroprotection in cellular and preclinical models of diseaseD019636. In this study, we investigated the therapeutic mechanisms of electroacupuncture (EA) treatment in 10090 with established diseaseD010300 and evaluated the relationship between EA, autophagy, and different neurons in the 10090 brain. We report that EA improves diseaseD010300 motor symptoms in 10090 and enhances (1) autophagy initiation (increased ncbi56208), (2) autophagosome biogenesis (increased ncbi11793, ncbi74244, ncbi245860, ncbi67526, ncbi77040, ncbi67841, and ncbi66734II), (3) autophagy flux/substrate degradation (decreased ncbi18226), and (4) mitophagy (increased ncbi68943 and ncbi57320) in neurons of the substantia nigra, striatum, hippocampus, and cortex (affected brain areas of diseaseD010300, diseaseD006816, and diseaseD000544). EA enhances autophagy initiation, autophagosome biogenesis, mitophagy, and autophagy flux/substrate degradation in certain brain areas. Our findings are the first to show that EA regulates neuronal autophagy and suggest that this convenient, inexpensive treatment has exciting therapeutic potential in diseaseD019636.
33852093		[Which interventions are recommended in the last phase of diseaseD006816?]diseaseD006816 is a chronically progressive and diseaseD019636, which leads to diseaseD003643 after 10 to 30 years of suffering and worsening. When suffering diseaseD006816 the 9606 will experience physical, cognitive and psychological issues, so that the 9606 won't be able to communicate or express his will in the end-of-life-phase of his disease. The problem is, after suffering a while the 9606 often won't be able to eat by himself, so a feeding tube must be implanted. In some cases a tracheostomy tube is needed because of the diseaseD012131. The cause of diseaseD003643 in most cases is an diseaseD007239 like a diseaseD012140. That's why it's most important when diagnosed with diseaseD006816 to advance care planning to end-of-life care like life-sustaining measures that engages 9606 in decision-making regarding future care, while they are still able to make and express decisions by themselves.
34655092	Association|chemicalD007501|diseaseD000544; Association|chemicalD007501|diseaseC536004; Association|chemicalD007501|chemicalD008903; Association|chemicalD007501|diseaseD020271; Association|chemicalD007501|diseaseD006816	Off-resonance saturation as an MRI method to quantify chemicalD008903- chemicalD007501 in the post-mortem brain.PURPOSE: To employ an off-resonance saturation method to measure the chemicalD008903-chemicalD007501 pool in the postmortem brain, which is an endogenous contrast agent that can give information on cellular chemicalD007501 status. METHODS: An off-resonance saturation acquisition protocol was implemented on a 7 Tesla preclinical scanner, and the contrast maps were fitted to an established analytical model. The method was validated by correlation and Bland-Altman analysis on a ferritin-containing phantom. chemicalD008903-chemicalD007501 maps were obtained from postmortem tissue of 9606 with diseaseD020271 characterized by brain chemicalD007501 accumulation, that is, diseaseD000544, diseaseD006816, and diseaseC536004, and validated with histology. Transverse relaxation rate and magnetic susceptibility values were used for comparison. RESULTS: In postmortem tissue, the chemicalD008903-chemicalD007501 contrast colocalizes with histological chemicalD007501 staining in all the cases. chemicalD007501 concentrations obtained via the off-resonance saturation method are in agreement with literature. CONCLUSIONS: Off-resonance saturation is an effective way to detect chemicalD007501 in gray matter structures and partially mitigate for the presence of myelin. If a reference region with little chemicalD007501 is available in the tissue, the method can produce quantitative chemicalD007501 maps. This method is applicable in the study of diseases characterized by brain chemicalD007501 accumulation and can complement existing chemicalD007501-sensitive parametric methods.
35767944		Heart Rate Variability in diseaseD006816: A Long-Term Longitudinal Study.INTRODUCTION: The aim of the study was to follow tonic and phasic autonomic nervous activity in diseaseD006816 (diseaseD006816) mutation carriers and 9606. METHODS: Evaluation of motor functions and total functional capacity was performed in 30 diseaseD006816 mutation carriers or 9606 at the beginning and in 22 subjects after 8-10 years. Continuous arterial blood pressure, heart rate (HR), and ECG at rest were measured, and HR variability analysis was performed in four different ways. A group of matched controls was also evaluated. RESULTS: Eighteen subjects were assorted in 3 groups: 6 diseaseD006816 mutation carriers without motor symptoms (diseaseD011547) who remained so (diseaseD011547-diseaseD011547); 6 early symptomatic 9606 (EHD) who remained so (EHD-EHD); and 6 early symptomatic 9606 who deteriorated to a late symptomatic (LHD) (EHD-LHD). At the beginning, sympathetic tonic activity in diseaseD011547 was elevated, according to mean arterial pressure (99 +- 10.6 mm Hg) higher than in controls (85 +- 8.7 mm Hg) and EHD (82 +- 9.9 mm Hg) (Dunnett's test, p < 0.05) and higher HR (78 +- 16 beats/min) than after 8-10 years (64 +- 11.3 beats/min) (paired t test, p < 0.05). There was also a decreased phasic sympathetic activity in EHD 9606 compared controls at the beginning (219 +- 106 vs. 664 +- 466 s2/Hz) and after 8-10 years (182 +- 136 vs. 1,012 +- 1,369 s2/Hz) (Dunnett's test, p < 0.05). In 9606 who deteriorated from EHD to LHD, there was a drop in phasic parasympathetic activity from 887 +- 433 to 230 +- 235 s2/Hz (paired t test, p < 0.05). CONCLUSIONS: Our long-term observational study provides important information on the timeline of ANS activity in diseaseD006816 progress. There was a temporary increase in cardiac and vascular sympathetic activity in diseaseD011547 subjects. The normalization of HR in diseaseD011547 subjects might indicate the approach of an outbreak of clinical disease phase.
32995944	Negative_Correlation|chemicalC483720|diseaseD006816; Association|chemicalC483720|ncbi1813; Association|chemicalC483720|chemicalD004298	Sigma-1 and ncbi1813 occupancy of chemicalC483720 in healthy volunteers and 9606 with diseaseD006816: a chemicalC558383 and chemicalC094948 PET study.PURPOSE: chemicalC483720 is an investigational drug for diseaseD006816 (diseaseD006816). chemicalC483720 was originally thought to act as a chemicalD004298 stabilizer. However, chemicalC483720 shows highest affinity to the sigma-1 receptor (S1R) and enhances neuroprotection via the S1R in preclinical studies. Using chemicalC558383 and chemicalC094948 PET, the purpose of this study was to assess in vivo target engagement/receptor occupancy of chemicalC483720 to the S1R and ncbi1813 (ncbi28503) at clinical relevant doses in healthy volunteers (HVs) and as proof-of-concept in a small number of 9606 with diseaseD006816. METHODS: Using chemicalC558383 PET (300 MBq, 0-90 min), 11 male HVs (chemicalC483720 0.5 to 90 mg; six dose groups) and three male 9606 with diseaseD006816 (chemicalC483720 90 mg) were investigated twice, without and 2 h after single dose of chemicalC483720. Using chemicalC094948 PET (200 MBq, 0-210 min), four male HVs were studied without and 2 h following chemicalC483720 administration (90 mg). Receptor occupancy was analyzed by the Lassen plot. RESULTS: S1R occupancy as function of chemicalC483720 dose (or plasma concentration) in HVs could be described by a three-parameter Hill equation with a Hill coefficient larger than one. A high degree of S1R occupancy (87% to 91%) was found throughout the brain at chemicalC483720 doses ranging from 22.5 to 90 mg. S1R occupancy was 43% at 1 mg chemicalC483720. In contrast, at 90 mg chemicalC483720, the ncbi28503 occupancy was only minimal (~ 3%). CONCLUSIONS: Our PET findings indicate that at clinically relevant single dose of 90 mg, chemicalC483720 acts as a selective S1R ligand showing near to complete S1R occupancy with negligible occupancy of the ncbi28503. The dose S1R occupancy relationship suggests cooperative binding of chemicalC483720 to the S1R. Our findings provide significant clarification about chemicalC483720's mechanism of action and support further use of the 45-mg twice-daily dose to achieve full and selective targeting of the S1R in future clinical trials of diseaseD019636. Clinical Trials.gov Identifier: NCT03019289 January 12, 2017; EUDRA-CT-Nr. 2016-001757-41.
34609495	Negative_Correlation|chemicalC000609690|diseaseD004409; Negative_Correlation|chemicalC000609690|diseaseD006816; Negative_Correlation|chemicalC000609690|diseaseD002819; Negative_Correlation|chemicalC000609690|diseaseD005879; Negative_Correlation|chemicalC000609690|diseaseD020323	Safety and Efficacy of Flexible-Dose chemicalC000609690 in Children and Adolescents With diseaseD005879: A Randomized Clinical Trial.Importance: diseaseD005879 is a diseaseD002658 characterized by childhood onset of diseaseD020323; treatments for diseaseD020323 are associated with safety concerns. chemicalC000609690 is a selective vesicular monoamine transporter 2 inhibitor approved for the treatment of diseaseD002819 associated with diseaseD006816 and diseaseD004409 in adults. Objective: To examine whether chemicalC000609690 is effective and safe for the treatment of diseaseD005879 in children and adolescents. Design, Setting, and Participants: This phase 2/3, randomized, double-masked, placebo-controlled, parallel-group, dose-titration study included children and adolescents (aged 6-16 years) with diseaseD005879 with active diseaseD020323 causing distress or impairment (ie, Yale Global diseaseD020323 Severity Scale-Total diseaseD020323 Score [YGTSS-TTS] >=20). The trial was conducted over 12 weeks, with 1 week of follow-up from February 2018 to November 2019 at 36 centers in the United States, Canada, Denmark, Russia, Serbia, and Spain. Data analysis was conducted from January 31 to April 22, 2020. Intervention: 9606 were randomized (1:1) to receive chemicalC000609690 or placebo, titrated during 7 weeks to an optimal level, followed by a 5-week maintenance period. The maximum total daily chemicalC000609690 dose was 48 mg/d. Main Outcomes and Measures: The primary efficacy end point was change from baseline to week 12 in YGTSS-TTS. Key secondary end points included changes in diseaseD005879-Clinical Global Impression, diseaseD005879-9606 Global Impression of Impact, and Child and Adolescent diseaseD005879-Quality of Life Activities of Daily Living subscale score. Safety was assessed based on treatment-emergent adverse events, vital signs, questionnaires, and laboratory parameters. Results: A total of 119 participants were randomized to chemicalC000609690 (59 participants; mean [SD] age, 11.5 [2.5] years; 53 [90%] 9606; 49 [83%] White; 3 [5%] Black) and placebo (60 participants; mean [SD] age, 11.5 [2.6] years; 51 [85%] 9606; 53 [88%] White; 3 [5%] Black). At week 12, the difference in YGTSS-TTS score was not significant between chemicalC000609690 and placebo (least squares mean difference, -0.7; 95% CI, -4.1 to 2.8; P = .69; Cohen d, -0.07). There were no nominally significant differences between groups for key secondary end points. Treatment-emergent adverse events were reported for 38 9606 (66%) and 33 9606 (56%) receiving chemicalC000609690 and placebo, respectively, and were generally mild or moderate. Conclusions and Relevance: In this study of chemicalC000609690 in children and adolescents with diseaseD005879, the primary efficacy end point was not met. No new safety signals were identified. These results may be informative for future studies of treatments for diseaseD020323 in diseaseD005879. Trial Registration: ClinicalTrials.gov Identifier: NCT03452943.
34012000		Double setback for ASO trials in diseaseD006816.
32684629		Addendum: American College of Medical Genetics and Genomics Standards and Guidelines for Clinical Genetics Laboratories, 2014 edition: technical standards and guidelines for diseaseD006816.
33136925	Positive_Correlation|chemicalD013747|diseaseD000071057; Association|chemicalD013747|diseaseD006816	diseaseD000071057 Associated With chemicalD013747 in diseaseD006816: A Case Report.
35387851		Teaching Video NeuroImage: Peculiar Hobby Horse Gait in diseaseC564708.
36854393		Genetic Testing in Clinical diseaseD009069: A Case-Based Review.Genetics are fundamental to understanding the pathophysiology of diseaseD020271, including diseaseD009069. Genetic testing in clinical practice has changed dramatically over the last few decades. While the likelihood of establishing an etiological diagnosis is greater now with increased access to testing and more advanced technologies, clinicians face challenges when deciding whether to test, then selecting the appropriate test, and ultimately interpreting and sharing the results with 9606 and families. In this review, we use a case-based approach to cover core aspects of genetic testing for the neurologist, namely, genetic testing in diseaseD010300, interpretation of inconclusive genetic test reports, and genetic testing for repeat expansion disorders using diseaseD006816 as a prototype.
36242718	Negative_Correlation|chemicalC000609690|diseaseD002819; Negative_Correlation|chemicalC000609690|diseaseD006816; Negative_Correlation|chemicalD013747|diseaseD002819	The Safety of chemicalC000609690 for diseaseD002819 in diseaseD006816: An Open-Label Extension Study.BACKGROUND: chemicalC000609690 is approved in the USA, China, Australia, Israel, Brazil, and South Korea for the treatment of diseaseD002819 associated with diseaseD006816. OBJECTIVE: We aimed to evaluate the long-term safety and tolerability of chemicalC000609690 for the treatment of diseaseD006816. METHODS: This open-label, single-arm, multi-center study included 9606 who completed a double-blind study (Rollover) and 9606 who converted overnight from a stable chemicalD013747 dose (Switch). Exposure-adjusted incidence rates (adverse events per person-year) were calculated. Efficacy was analyzed using a stable post-titration timepoint (8 weeks). Changes in the Unified diseaseD006816 Rating Scale total motor score and total maximal diseaseD002819 score from baseline to week 8, as well as those from week 8 to week 145 (or the last visit on the study drug if that occurred earlier), were evaluated as both efficacy and safety endpoints during the study. RESULTS: Of 119 9606 (Rollover, n = 82; Switch, n = 37), 100 (84%) completed >= 1 year of treatment. End-of-study exposure-adjusted incidence rates for adverse events in Rollover and Switch, respectively, were: any, 2.57 and 4.02; serious, 0.11 and 0.14; leading to dose suspension, 0.05 and 0.04. Common adverse events (>= 4% either cohort) included diseaseD006970 (Rollover, 20%; Switch, 30%), diseaseD003866 (32%; 22%), diseaseD001007 (27%; 35%), diseaseD007319 (23%; 16%), and diseaseD017109 (6%; 11%). Adverse events of interest included suicidality (9%; 5%) and diseaseD010302 (4%; 8%). Mean dose at week 8 was 38.1 mg (Rollover) and 36.5 mg (Switch). Mean dose across cohorts after titration was 37.6 mg; at the final visit, mean dose across cohorts was 45.7 mg. 9606 showed minimal change in the Unified diseaseD006816 Rating Scale total maximal diseaseD002819 scores with stable dosing from weeks 8-145 or at the end of treatment, but total motor score increased versus week 8 (mean change [standard deviation]: 8.2 [11.9]). There were no unexpected adverse events upon drug withdrawal, and mean (standard deviation) total maximal diseaseD002819 scores increased 4.7 (4.6) units from week 8 to 1-week follow-up. CONCLUSIONS: Adverse events observed with long-term chemicalC000609690 exposure were consistent with previous studies. Reductions in diseaseD002819 persisted over time. Upon treatment cessation, there was no unexpected worsening of diseaseD002819. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT01897896.
35626701	Negative_Correlation|chemicalD005680|diseaseD006816	Restoration of ncbi24225, ncbi360616, and D2R Expression Following Intravenous Infusion of 9606 Immature Dental Pulp Stem Cells in diseaseC565747-NP 10116 Model.diseaseD006816 (diseaseD006816) is a diseaseD020271, which leads to the onset of diseaseD003072. diseaseD006816 is characterized by the loss of chemicalD005680 (chemicalD005680)ergic medium spiny neurons (MSNs). To date, there is no treatment for diseaseD006816. Mesenchymal stem cells (MSCs) provide a substantial therapeutic opportunity for the diseaseD006816 treatment. Herein, we investigated the therapeutic potential of 9606 immature dental pulp stem cells (AV90), a special type of MSC originated from the neural crest, for diseaseD006816 treatment. Two different doses of AV90 were intravenously administrated in a subacute chemicalC015392 (chemicalC015392)-induced 10116 model. We demonstrated AV90 homing in the striatum, cortex and subventricular zone using specific markers for 9606 cells. Thirty days after AV90 administration, the cells found in the brain are still express hallmarks of undifferentiated MSC. Immunohistochemistry quantities analysis revealed a significant increase in the number of ncbi24225, ncbi360616 and D2R positive stained cells in the striatum and cortex in the groups that received AV90. The differences were more expressive in animals that received only one administration of AV90. Altogether, these data suggest that the intravenous administration of hIDPSCs can restore the ncbi24225, ncbi360616 and D2R expression, promoting neuroprotection and neurogenesis.
33106388		Association of Dilated Perivascular Spaces and Disease Severity in 9606 With diseaseD006816.OBJECTIVE: To quantify the percent volume of dilated perivascular space (PVS) in the subcortical forebrain in 9606 with early diseaseD006816 (diseaseD006816) and to explore the relationship between PVS and disease severity. METHODS: MRI scans were performed on 25 9606 with diseaseD006816 and 23 healthy age-matched controls at Massachusetts General Hospital. The imaging data were analyzed with a novel algorithm to determine regional PVS volume. A fractional logistic regression analysis was used to quantify the association between regional percent PVS volume and (1) disease designation (diseaseD006816 or control) and (2) disease severity as assessed by normalized caudate volume. RESULTS: 9606 with diseaseD006816 had the greatest percent volume of diseaseD002311 in the putamen (left putamen: odds ratio 2.06 [95% confidence interval (CI) 1.62-2.62], diseaseD006816 3.27% [95% CI 2.83-3.78] vs controls 1.62% [95% CI 1.32-1.97], p fdr < 0.001; right putamen: odds ratio 1.66 [95% CI 1.33-2.08], diseaseD006816 3.43% [95% CI 2.94-4.01] vs controls 2.09% [95% CI 1.79-2.45], p fdr < 0.001) and several subcortical white matter regions compared to controls. diseaseD002311 increased with disease severity. CONCLUSIONS: The objective quantification of diseaseD002311 suggests that PVS burden is high, is associated with disease severity, and may affect the distribution and success of treatments administered either intrathecally such as antisense chemicalD009841 or by intraparenchymal administration such as cell and gene therapies. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that increased diseaseD002311 is associated with worse diseaseD006816 severity. The study is rated Class II because of the cross-sectional design.
32302684	Association|diseaseD006816|ncbi27089; Association|diseaseD006816|ncbi1537; Association|diseaseD006816|ncbi7384	ncbi1537, ncbi6389, ncbi7384, ncbi27089, and ncbi6390 might be important biomarkers in kidney transplant rejection.BACKGROUND: Kidney transplant rejection is considered as a vital factor of diseaseD051437. Therefore, it's necessary to search for effective biomarkers for kidney transplant surveillance. METHODS: In this study, we conducted time-series gene expression profiles analysis of samples from kidney transplant 9606 with different post-transplant days through weighted gene co-expression network analysis (WGCNA). Associations between gene co-expression modules and days post-transplant were determined through spearman rank correlation analysis. Potential kidney transplant rejection-related modules were subjected to gene functional enrichment analysis through clusterProfiler and protein-protein interaction analysis via STRING database. RESULTS: A total of 11 gene co-expression modules were identified, and the pink module which was mainly involved in "energy derivation by oxidation of organic compounds" and "diseaseD006816" showed significant correlation with the phenotypic trait "days post-transplant". ncbi1537, ncbi6389, ncbi7384, ncbi27089, and ncbi6390 in the pink module exhibited high scores in the protein-protein interaction network analysis. CONCLUSIONS: We reported several potential genes may be associated with the kidney transplant rejection, which should provide novel biomarkers for kidney transplant surveillance.
34448021	Association|diseaseD006816|ncbi3064	Early white matter pathology in the fornix of the limbic system in diseaseD006816.diseaseD006816 (diseaseD006816) is a fatal diseaseD019636 caused by an expanded CAG repeat in the ncbi3064 (ncbi3064) gene. The typical motor symptoms have been associated with diseaseD001480. However, diseaseD019954 often precede the motor component and may be due to changes in the limbic system. Recent work has indicated pathology in the hypothalamus in diseaseD006816 but other parts of the limbic system have not been extensively studied. Emerging evidence suggests that changes in diseaseD006816 also include white matter pathology. Here we investigated if the main white matter tract of the limbic system, the fornix, is affected in diseaseD006816. We demonstrate that the fornix is 34% smaller already in prodromal diseaseD006816 and 41% smaller in manifest diseaseD006816 compared to controls using volumetric analyses of MRI of the IMAGE-diseaseD006816 study. In post-mortem fornix tissue from diseaseD006816 cases, we confirm the smaller fornix volume in diseaseD006816 which is accompanied by signs of myelin breakdown and reduced levels of the transcription factor myelin regulating factor but detect no loss of oligodendrocytes. Further analyses using RNA-sequencing demonstrate downregulation of oligodendrocyte identity markers in the fornix of diseaseD006816 cases. Analysis of differentially expressed genes based on transcription-factor/target-gene interactions also revealed enrichment for binding sites of ncbi23512 and ncbi2146, components of the Polycomb Repressive Complex 2, as well as RE1 Regulation Transcription Factor. Taken together, our data show that there is early white matter pathology of the fornix in the limbic system in diseaseD006816 likely due to a combination of reduction in oligodendrocyte genes and myelin break down.
33745925	Positive_Correlation|chemicalC015392|ncbi25402; Positive_Correlation|chemicalC015392|diseaseD001259; Positive_Correlation|chemicalC015392|diseaseD051437; Positive_Correlation|chemicalC015392|ncbi24835	Elderberry diet ameliorates motor function and prevents oxidative stress-induced cell death in 10116 models of diseaseD006816.diseaseD006816 (diseaseD006816) is an diseaseD020271 which begins in the striatum and then spreads to other neural areas. Known as a progressive diseaseD003072, diseaseD006816 has no efficient therapy. Although the exact mechanism of diseaseD006816 is still unknown, several different etiological processes such as oxidative stress have been shown to play critical roles. Also, the current evidence indicates a strong correlation between immune activation and diseaseD015441 induced by diseaseD000090862 and apoptotic agents in diseaseD019636. Thus, natural products like Elderberry (138949) could be considered as a novel and potential therapeutic candidate for the treatment of this disease. In this study 138949 was added to the daily ration of ordinary 10116 for two months in order to ameliorate diseaseD007249 and oxidative responses in 10116 injected with chemicalC015392 (chemicalC015392) in an experimental model of diseaseD006816. Using Rotarod and electromyography setups, we showed that 138949 diet significantly recovered diseaseD051437 and diseaseD001259 in chemicalC015392 injected 10116 compared to the control group. Also, the molecular findings implied that 138949 diet led to a significant drop in chemicalC015392 induced growth in ncbi25402 and ncbi24835 concentration. The treatment also improved striatal antioxidative capacity by a significant reduction in ROS and a remarkable rise in chemicalD005978, which might be correlated with motor recovery in the tests. In sum, the findings demonstrate the advantages of 138949 treatment in the diseaseD006816 10116 model with a score of beneficial anti-oxidative and anti-diseaseD007249 effects.
34583142		Measures of postural control and mobility during dual-tasking as candidate markers of instability in diseaseD006816.BACKGROUND: Individuals with diseaseD006816 (diseaseD006816) have impairments in performing dual-tasks, however, there is limited information about the effects of changing postural and cognitive demands as well as which measures are best suited as markers of underlying motor-cognitive interference. METHODS: Forty-three individuals with diseaseD006816 and 15 healthy controls (HC) completed single tasks of walking (Timed Up & Go (TUG), 7 m walk), standing (feet together, feet apart and foam surface) and seated cognitive performance (Stroop, Symbol Digit Modalities Test (SDMT), Delis-Kaplan Executive Function System (DKEFS) Sorting test) and dual cognitive-motor tasks while standing (+ Stroop) and walking (+ DKEFS, TUG cognitive). APDM Opal sensors recorded measures of postural sway and time to complete motor tasks. RESULTS: Individuals with diseaseD006816 had a greater increase in standing postural sway compared to HC from single to dual-tasks and with changes to support surface. Both groups demonstrated a decrease in gait performance during the TUG cognitive, however, this difference was greater in people with diseaseD006816 compared to HC. While those with diseaseD006816 showed a greater dual-task motor cost compared to HC, both groups behaved similarly as condition complexity increased. CONCLUSIONS: Standing postural sway is a more sensitive marker of instability than change in standard gait speed, particularly under dual-task conditions. The more complex TUG cognitive is a sensitive measure of walking dual-task performance. The results of this study provide insights about the nature of diseaseD003072 in diseaseD006816 and provide support for a distinction between static and dynamic postural control mechanisms during performance of dual-tasks.
36334065		Post-mortem 7T MR imaging and neuropathology in middle stage juvenile-onset diseaseD006816: A case report.
33757575	Association|diseaseD006816|ncbi6449; Association|diseaseD019636|ncbi6449; Association|ncbi4287|ncbi6449; Association|diseaseD020754|ncbi6449; Association|diseaseD020191|ncbi6449; Association|chemicalC097188|ncbi6449; Association|ncbi6311|ncbi6449; Association|diseaseD004194|ncbi6449; Association|diseaseD019578|ncbi6449	ncbi6449 associates with intracellular aggregates in diseaseD019636.Intracellular aggregates are a common pathological hallmark of diseaseD019636 such as diseaseD030342, diseaseD000690 (diseaseD000690), diseaseD010300 (diseaseD010300), and diseaseD019578 (diseaseD019578). Aggregates are mainly formed by aberrant disease-specific proteins and are accompanied by accumulation of other aggregate-interacting proteins. Although aggregate-interacting proteins have been considered to modulate the formation of aggregates and to be involved in molecular mechanisms of disease progression, the components of aggregate-interacting proteins remain unknown. In this study, we showed that ncbi6449 (ncbi6449) is an aggregate-interacting protein in diseaseD019636. Immunohistochemistry showed that ncbi6449 interacted with intracellular aggregates in diseaseD006816 (diseaseD006816) cell models and neurons of diseaseD006816 model 10090. We also revealed that ncbi6449 colocalized with intracellular aggregates in postmortem brains of 9606 with diseaseD004194 including diseaseD020754, ncbi6311, ncbi4287, and diseaseD020191. In addition, ncbi6449 colocalized with glial cytoplasmic inclusions in the brains of diseaseD019578 9606, whereas no accumulation of ncbi6449 was observed in neurons of diseaseD010300 and diseaseD000690 9606. In vitro study showed that ncbi6449 bound to chemicalC097188 aggregates through its C-terminal domain and ncbi6449 overexpression reduced intracellular aggregates. These results suggest that ncbi6449 may play a role in the formation of aggregates and may act as potential modifier of molecular pathological mechanisms of diseaseD004194 and diseaseD019578.
33926896		Complete Evaluation of diseaseD003704: PET and MRI Correlation and Diagnosis for the Neuroradiologist.This article will familiarize neuroradiologists with the pathophysiology, clinical findings, and standard MR imaging and PET imaging features of multiple forms of diseaseD003704 as well as new emerging techniques. Cases were compiled from multiple institutions with the goal of improved diagnostic accuracy and improved 9606 care as well as information about biomarkers on the horizon. diseaseD003704 topics addressed include the following: diseaseD000544, diseaseD057180, diseaseD016657, diseaseD020961, diseaseD010300 and diseaseD010300 variants, diseaseD000690, diseaseD019578, diseaseD006816 diseaseD015140, and diseaseD007562.
